{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:03:07Z","timestamp":1789675387054,"version":"4.0.1"},"reference-count":316,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10495-026-02409-9","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:21:12Z","timestamp":1787340072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-2754","authenticated-orcid":false,"given":"Sourio","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-0348","authenticated-orcid":false,"given":"Sumon","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6092-7162","authenticated-orcid":false,"given":"Subhajit","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-8614","authenticated-orcid":false,"given":"Udit","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-1883","authenticated-orcid":false,"given":"Sumoyee","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-6527","authenticated-orcid":false,"given":"Arghya","family":"Adhikary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-3481","authenticated-orcid":false,"given":"Gaurisankar","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-0693","authenticated-orcid":false,"given":"Tanya","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2409_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden M, Spranger S (2025) Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol 25:353\u2013369. https:\/\/doi.org\/10.1038\/s41577-024-01111-8","journal-title":"Nat Rev Immunol"},{"key":"2409_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ccell.2022.06.007","volume":"40","author":"M Bassani-Sternberg","year":"2022","unstructured":"Bassani-Sternberg M, Harari A (2022) Immune pressure sculps tumor cells and trims high-quality mutations. Cancer Cell 40:717\u2013719. https:\/\/doi.org\/10.1016\/j.ccell.2022.06.007","journal-title":"Cancer Cell"},{"key":"2409_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","volume":"48","author":"MD Wellenstein","year":"2018","unstructured":"Wellenstein MD, de Visser KE (2018) Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48:399\u2013416. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.004","journal-title":"Immunity"},{"key":"2409_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48:812\u2013830. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023","journal-title":"Immunity"},{"key":"2409_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium and escape. Curr Opin Immunol 27:16\u201325. https:\/\/doi.org\/10.1016\/j.coi.2014.01.004","journal-title":"Curr Opin Immunol"},{"key":"2409_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"2409_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1804","author":"MM Gubin","year":"2022","unstructured":"Gubin MM, Vesely MD (2022) Cancer immunoediting in the era of immuno-oncology. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1804. .1804.2022","journal-title":"Clin Cancer Res clincanres"},{"key":"2409_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc3246","volume":"12","author":"T Blankenstein","year":"2012","unstructured":"Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012) The determinants of tumour immunogenicity. Nat Rev Cancer 12:307\u2013313. https:\/\/doi.org\/10.1038\/nrc3246","journal-title":"Nat Rev Cancer"},{"key":"2409_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-023-01430-8","volume":"16","author":"S Liu","year":"2023","unstructured":"Liu S, Sun Q, Ren X (2023) Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol 16:38. https:\/\/doi.org\/10.1186\/s13045-023-01430-8","journal-title":"J Hematol Oncol"},{"key":"2409_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","volume":"1284","author":"MD Vesely","year":"2013","unstructured":"Vesely MD, Schreiber RD (2013) Cancer immunoediting: antigens, mechanisms and implications to cancer immunotherapy. Ann N Y Acad Sci 1284:1\u20135. https:\/\/doi.org\/10.1111\/nyas.12105","journal-title":"Ann N Y Acad Sci"},{"key":"2409_CR11","doi-asserted-by":"publisher","first-page":"e49020","DOI":"10.7554\/eLife.49020","volume":"8","author":"S Wang","year":"2019","unstructured":"Wang S, He Z, Wang X et al (2019) Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife 8:e49020. https:\/\/doi.org\/10.7554\/eLife.49020","journal-title":"Elife"},{"key":"2409_CR12","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD (2023) Advances in cancer immunotherapies. Cell 186:1814\u20131814. https:\/\/doi.org\/10.1016\/j.cell.2023.02.039","journal-title":"Cell"},{"key":"2409_CR13","doi-asserted-by":"publisher","first-page":"104588","DOI":"10.1016\/j.critrevonc.2024.104588","volume":"206","author":"C-Y Hsu","year":"2025","unstructured":"Hsu C-Y, Pallathadka H, Jasim SA et al (2025) Innovations in cancer immunotherapy: a comprehensive overview of recent breakthroughs and future directions. Crit Rev Oncol Hematol 206:104588. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104588","journal-title":"Crit Rev Oncol Hematol"},{"key":"2409_CR14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"key":"2409_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017","journal-title":"Cell"},{"key":"2409_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52:17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011","journal-title":"Immunity"},{"key":"2409_CR17","doi-asserted-by":"publisher","first-page":"107327482513814","DOI":"10.1177\/10732748251381441","volume":"32","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Basak U, Mukherjee S et al (2025) Cancer stem cells decide the fate of cancer immunotherapy by remodeling tumor microenvironment. Cancer Control 32:10732748251381441. https:\/\/doi.org\/10.1177\/10732748251381441","journal-title":"Cancer Control"},{"key":"2409_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-022-05408-1","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang T, Su W et al (2022) Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis 13:1\u201314. https:\/\/doi.org\/10.1038\/s41419-022-05408-1","journal-title":"Cell Death Dis"},{"key":"2409_CR19","doi-asserted-by":"publisher","first-page":"607670","DOI":"10.3389\/fcell.2020.607670","volume":"8","author":"E Alvarado-Ortiz","year":"2020","unstructured":"Alvarado-Ortiz E, de la Cruz-L\u00f3pez KG, Becerril-Rico J et al (2020) Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front Cell Dev Biol 8:607670. https:\/\/doi.org\/10.3389\/fcell.2020.607670","journal-title":"Front Cell Dev Biol"},{"key":"2409_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26:199\u2013212. https:\/\/doi.org\/10.1038\/s41418-018-0246-9","journal-title":"Cell Death Differ"},{"key":"2409_CR21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","volume":"5","author":"G Efe","year":"2024","unstructured":"Efe G, Rustgi AK, Prives C (2024) p53 at the crossroads of tumor immunity. Nat Cancer 5:983\u2013995. https:\/\/doi.org\/10.1038\/s43018-024-00796-z","journal-title":"Nat Cancer"},{"key":"2409_CR22","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","volume":"1876","author":"LJH Borrero","year":"2021","unstructured":"Borrero LJH, El-Deiry WS (2021) Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 1876:188556. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188556","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2409_CR23","doi-asserted-by":"publisher","first-page":"1148389","DOI":"10.3389\/fmolb.2023.1148389","volume":"10","author":"L Carlsen","year":"2023","unstructured":"Carlsen L, Zhang S, Tian X et al (2023) The role of p53 in anti-tumor immunity and response to immunotherapy. Front Mol Biosci 10:1148389. https:\/\/doi.org\/10.3389\/fmolb.2023.1148389","journal-title":"Front Mol Biosci"},{"key":"2409_CR24","doi-asserted-by":"publisher","first-page":"e1285990","DOI":"10.1080\/2162402X.2017.1285990","volume":"6","author":"K Shamalov","year":"2017","unstructured":"Shamalov K, Levy SN, Horovitz-Fried M, Cohen CJ (2017) The mutational status of p53 can influence its recognition by human T-cells. Oncoimmunology 6:e1285990. https:\/\/doi.org\/10.1080\/2162402X.2017.1285990","journal-title":"Oncoimmunology"},{"key":"2409_CR25","doi-asserted-by":"publisher","unstructured":"Malekzadeh P, Pasetto A, Robbins PF et al (2021) Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest 129:e123791. https:\/\/doi.org\/10.1172\/JCI123791","DOI":"10.1172\/JCI123791"},{"key":"2409_CR26","doi-asserted-by":"publisher","first-page":"707734","DOI":"10.3389\/fimmu.2021.707734","volume":"12","author":"V Chasov","year":"2021","unstructured":"Chasov V, Zaripov M, Mirgayazova R et al (2021) Promising new tools for targeting p53 mutant cancers: humoral and cell-based immunotherapies. Front Immunol 12:707734. https:\/\/doi.org\/10.3389\/fimmu.2021.707734","journal-title":"Front Immunol"},{"key":"2409_CR27","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.3390\/cancers14143500","volume":"14","author":"M Pereira","year":"2022","unstructured":"Pereira M, Matuszewska K, Glogova A, Petrik J (2022) Mutant p53, the mevalonate pathway and the tumor microenvironment regulate tumor response to statin therapy. Cancers 14:3500. https:\/\/doi.org\/10.3390\/cancers14143500","journal-title":"Cancers (Basel)"},{"key":"2409_CR28","doi-asserted-by":"publisher","first-page":"602328","DOI":"10.3389\/fmolb.2020.602328","volume":"7","author":"X Lin","year":"2020","unstructured":"Lin X, Wang L, Xie X et al (2020) Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma. Front Mol Biosci 7:602328. https:\/\/doi.org\/10.3389\/fmolb.2020.602328","journal-title":"Front Mol Biosci"},{"key":"2409_CR29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1158\/0008-5472.CAN-12-3810","volume":"73","author":"G Guo","year":"2013","unstructured":"Guo G, Marrero L, Rodriguez P et al (2013) Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res 73:1668\u20131675. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3810","journal-title":"Cancer Res"},{"key":"2409_CR30","doi-asserted-by":"publisher","first-page":"152177","DOI":"10.1016\/j.imbio.2022.152177","volume":"227","author":"L Xu","year":"2022","unstructured":"Xu L, Xie X, Li X et al (2022) Inflammatory level under different p53 mutation status and the regulation role of curcumin in tumor microenvironment. Immunobiology 227:152177. https:\/\/doi.org\/10.1016\/j.imbio.2022.152177","journal-title":"Immunobiology"},{"key":"2409_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s42003-022-03675-4","volume":"5","author":"Y Shi","year":"2022","unstructured":"Shi Y, Xie T, Wang B et al (2022) Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol 5:757. https:\/\/doi.org\/10.1038\/s42003-022-03675-4","journal-title":"Commun Biol"},{"key":"2409_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","volume":"45","author":"MH Andersen","year":"2023","unstructured":"Andersen MH (2023) Tumor microenvironment antigens. Semin Immunopathol 45:253\u2013264. https:\/\/doi.org\/10.1007\/s00281-022-00966-0","journal-title":"Semin Immunopathol"},{"key":"2409_CR33","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/med.21765","volume":"41","author":"H Sadeghi Rad","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME et al (2021) Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev 41:1474\u20131498. https:\/\/doi.org\/10.1002\/med.21765","journal-title":"Med Res Rev"},{"key":"2409_CR34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, Song E (2022) Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 43:523\u2013545. https:\/\/doi.org\/10.1016\/j.it.2022.04.010","journal-title":"Trends Immunol"},{"key":"2409_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B et al (2024) Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9:274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/jcp.54.9.669","volume":"54","author":"D J\u00e4ger","year":"2001","unstructured":"J\u00e4ger D, J\u00e4ger E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669\u2013674. https:\/\/doi.org\/10.1136\/jcp.54.9.669","journal-title":"J Clin Pathol"},{"key":"2409_CR37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1349-7006.2004.tb02182.x","volume":"95","author":"Y Kawakami","year":"2004","unstructured":"Kawakami Y, Fujita T, Matsuzaki Y et al (2004) Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95:784\u2013791. https:\/\/doi.org\/10.1111\/j.1349-7006.2004.tb02182.x","journal-title":"Cancer Sci"},{"key":"2409_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen SP, L\u00f6ffler MW, Rammensee H-G, Brossart P (2020) Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol 17:595\u2013610. https:\/\/doi.org\/10.1038\/s41571-020-0387-x","journal-title":"Nat Rev Clin Oncol"},{"key":"2409_CR39","doi-asserted-by":"publisher","first-page":"970623","DOI":"10.3389\/fonc.2022.970623","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang J, Guo X, Jin B, Zhu Q (2022) Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization. Front Oncol 12:970623. https:\/\/doi.org\/10.3389\/fonc.2022.970623","journal-title":"Front Oncol"},{"key":"2409_CR40","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.crmeth.2024.100906","volume":"4","author":"X Yi","year":"2024","unstructured":"Yi X, Zhao H, Hu S et al (2024) Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. Cell Rep Methods 4:100906. https:\/\/doi.org\/10.1016\/j.crmeth.2024.100906","journal-title":"Cell Rep Methods"},{"key":"2409_CR41","doi-asserted-by":"publisher","first-page":"114576","DOI":"10.1016\/j.intimp.2025.114576","volume":"154","author":"X Guo","year":"2025","unstructured":"Guo X, Bai J, Wang X et al (2025) Evoking the Cancer-immunity cycle by targeting the tumor-specific antigens in Cancer immunotherapy. Int Immunopharmacol 154:114576. https:\/\/doi.org\/10.1016\/j.intimp.2025.114576","journal-title":"Int Immunopharmacol"},{"key":"2409_CR42","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko V, Rosenberg SA (2020) Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38:454\u2013472. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.013","journal-title":"Cancer Cell"},{"key":"2409_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W et al (2023) Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 8:9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR44","doi-asserted-by":"publisher","first-page":"833017","DOI":"10.3389\/fimmu.2022.833017","volume":"13","author":"MJW Sim","year":"2022","unstructured":"Sim MJW, Sun PD (2022) T cell recognition of tumor neoantigens and insights into T cell immunotherapy. Front Immunol 13:833017. https:\/\/doi.org\/10.3389\/fimmu.2022.833017","journal-title":"Front Immunol"},{"key":"2409_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","volume":"21","author":"J Budczies","year":"2024","unstructured":"Budczies J, Kazdal D, Menzel M et al (2024) Tumour mutational burden: clinical utility, challenges and emerging improvements. Nat Rev Clin Oncol 21:725\u2013742. https:\/\/doi.org\/10.1038\/s41571-024-00932-9","journal-title":"Nat Rev Clin Oncol"},{"key":"2409_CR46","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1535-7163.MCT-20-0161","volume":"19","author":"P Riviere","year":"2020","unstructured":"Riviere P, Goodman AM, Okamura R et al (2020) High tumor mutational burden correlates with longer survival in immunotherapy-na\u00efve patients with diverse cancers. Mol Cancer Ther 19:2139\u20132145. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0161","journal-title":"Mol Cancer Ther"},{"key":"2409_CR47","doi-asserted-by":"publisher","first-page":"e001111","DOI":"10.1136\/jitc-2020-001111","volume":"8","author":"MY Lee","year":"2020","unstructured":"Lee MY, Jeon JW, Sievers C, Allen CT (2020) Antigen processing and presentation in cancer immunotherapy. J Immunother Cancer 8:e001111. https:\/\/doi.org\/10.1136\/jitc-2020-001111","journal-title":"J Immunother Cancer"},{"key":"2409_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imm.12675","volume":"150","author":"E Reeves","year":"2017","unstructured":"Reeves E, James E (2017) Antigen processing and immune regulation in the response to tumours. Immunology 150:16\u201324. https:\/\/doi.org\/10.1111\/imm.12675","journal-title":"Immunology"},{"key":"2409_CR49","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1007\/s00432-023-04737-8","volume":"149","author":"A Kallingal","year":"2023","unstructured":"Kallingal A, Olszewski M, Maciejewska N et al (2023) Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol 149:8131\u20138141. https:\/\/doi.org\/10.1007\/s00432-023-04737-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"2409_CR50","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL (2022) A guide to antigen processing and presentation. Nat Rev Immunol 22:751\u2013764. https:\/\/doi.org\/10.1038\/s41577-022-00707-2","journal-title":"Nat Rev Immunol"},{"key":"2409_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01208-8","author":"F Huber","year":"2025","unstructured":"Huber F, Bassani-Sternberg M (2025) Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-025-01208-8","journal-title":"Nat Rev Immunol"},{"key":"2409_CR52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.trecan.2020.12.005","volume":"7","author":"JT George","year":"2021","unstructured":"George JT, Levine H (2021) Implications of tumor-immune coevolution on cancer evasion and optimized immunotherapy. Trends Cancer 7:373\u2013383. https:\/\/doi.org\/10.1016\/j.trecan.2020.12.005","journal-title":"Trends Cancer"},{"key":"2409_CR53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329\u2013360. https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104803","journal-title":"Annu Rev Immunol"},{"key":"2409_CR54","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1016\/j.cell.2022.09.027","volume":"185","author":"SK Varanasi","year":"2022","unstructured":"Varanasi SK, Kaech SM, Bui JD (2022) SnapShot: cancer immunoediting. Cell 185:4038\u20134038. https:\/\/doi.org\/10.1016\/j.cell.2022.09.027","journal-title":"Cell"},{"key":"2409_CR55","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.21037\/atm-20-4750","volume":"9","author":"N Okwundu","year":"2021","unstructured":"Okwundu N, Grossman D, Hu-Lieskovan S et al (2021) The dark side of immunotherapy. Ann Transl Med 9:1041. https:\/\/doi.org\/10.21037\/atm-20-4750","journal-title":"Ann Transl Med"},{"key":"2409_CR56","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124:109821. https:\/\/doi.org\/10.1016\/j.biopha.2020.109821","journal-title":"Biomed Pharmacother"},{"key":"2409_CR57","doi-asserted-by":"publisher","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","volume":"12","author":"LA Emens","year":"2024","unstructured":"Emens LA, Romero PJ, Anderson AC et al (2024) Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer 12:e009063. https:\/\/doi.org\/10.1136\/jitc-2024-009063","journal-title":"J Immunother Cancer"},{"key":"2409_CR58","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12672-023-00787-z","volume":"14","author":"S Mukherjee","year":"2023","unstructured":"Mukherjee S, Chakraborty S, Basak U et al (2023) Breast cancer stem cells generate immune-suppressive T regulatory cells by secreting TGF\u03b2 to evade immune-elimination. Discov Oncol 14:220. https:\/\/doi.org\/10.1007\/s12672-023-00787-z","journal-title":"Discov Oncol"},{"key":"2409_CR59","doi-asserted-by":"publisher","unstructured":"Basak U, Chakraborty S, Mukherjee S et al (2025) Breast cancer stem cells convert anti-tumor CD4+\u2009T cells to pro-tumor T regulatory cells: Potential role of exosomal FOXP3. Cell Immunol. https:\/\/doi.org\/10.1016\/j.cellimm.2025.104931","DOI":"10.1016\/j.cellimm.2025.104931"},{"key":"2409_CR60","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.insi.2025.100071","volume":"1","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Basak U, Mukherjee S et al (2025) Down-regulation and reduced surface-presentation of neoantigens in cancer stem cells decide the fate of cancer immunotherapy: an in-silico mechanistic hypothesis. Silico Res Biomed 1:100071. https:\/\/doi.org\/10.1016\/j.insi.2025.100071","journal-title":"Silico Res Biomed"},{"key":"2409_CR61","doi-asserted-by":"publisher","first-page":"217076","DOI":"10.1016\/j.canlet.2024.217076","volume":"597","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhao Y, Song H et al (2024) Metabolic reprogramming in tumor immune microenvironment: impact on immune cell function and therapeutic implications. Cancer Lett 597:217076. https:\/\/doi.org\/10.1016\/j.canlet.2024.217076","journal-title":"Cancer Lett"},{"key":"2409_CR62","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","volume":"87","author":"J Dunn","year":"2017","unstructured":"Dunn J, Rao S (2017) Epigenetics and immunotherapy: the current state of play. Mol Immunol 87:227\u2013239. https:\/\/doi.org\/10.1016\/j.molimm.2017.04.012","journal-title":"Mol Immunol"},{"key":"2409_CR63","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1007\/s00018-018-2908-7","volume":"75","author":"N Arenas-Ramirez","year":"2018","unstructured":"Arenas-Ramirez N, Sahin D, Boyman O (2018) Epigenetic mechanisms of tumor resistance to immunotherapy. Cell Mol Life Sci 75:4163\u20134176. https:\/\/doi.org\/10.1007\/s00018-018-2908-7","journal-title":"Cell Mol Life Sci"},{"key":"2409_CR64","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/2159-8290.CD-23-0216","volume":"14","author":"MH Dias","year":"2024","unstructured":"Dias MH, Friskes A, Wang S et al (2024) Paradoxical activation of oncogenic signaling as a cancer treatment strategy. Cancer Discov 14:1276\u20131301. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0216","journal-title":"Cancer Discov"},{"key":"2409_CR65","doi-asserted-by":"publisher","unstructured":"Garcia GG, Schmidt CJ, Hajal C (2024) The tumor microenvironment in therapy resistance. Front Lab Chip Technol. https:\/\/doi.org\/10.3389\/frlct.2024.1420233","DOI":"10.3389\/frlct.2024.1420233"},{"key":"2409_CR66","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","volume":"30","author":"YR Murciano-Goroff","year":"2020","unstructured":"Murciano-Goroff YR, Warner AB, Wolchok JD (2020) The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res 30:507\u2013519. https:\/\/doi.org\/10.1038\/s41422-020-0337-2","journal-title":"Cell Res"},{"key":"2409_CR67","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","volume":"24","author":"L Akkari","year":"2024","unstructured":"Akkari L, Amit I, Bronte V et al (2024) Defining myeloid-derived suppressor cells. Nat Rev Immunol 24:850\u2013857. https:\/\/doi.org\/10.1038\/s41577-024-01062-0","journal-title":"Nat Rev Immunol"},{"key":"2409_CR68","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fimmu.2020.00783","volume":"11","author":"A Hou","year":"2020","unstructured":"Hou A, Hou K, Huang Q et al (2020) Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front Immunol 11:783. https:\/\/doi.org\/10.3389\/fimmu.2020.00783","journal-title":"Front Immunol"},{"key":"2409_CR69","doi-asserted-by":"publisher","unstructured":"Basak U, Sarkar T, Mukherjee S et al (2023) Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1295257","DOI":"10.3389\/fimmu.2023.1295257"},{"key":"2409_CR70","doi-asserted-by":"publisher","first-page":"1655176","DOI":"10.3389\/fimmu.2025.1655176","volume":"16","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee S, Ghosh A, Chakraborty S et al (2025) Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis. Front Immunol 16:1655176. https:\/\/doi.org\/10.3389\/fimmu.2025.1655176","journal-title":"Front Immunol"},{"key":"2409_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C (2021) Cytokine regulation and function in T cells. Annu Rev Immunol 39:51\u201376. https:\/\/doi.org\/10.1146\/annurev-immunol-061020-053702","journal-title":"Annu Rev Immunol"},{"key":"2409_CR72","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC et al (2019) Cytokines in clinical cancer immunotherapy. Br J Cancer 120:6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y","journal-title":"Br J Cancer"},{"key":"2409_CR73","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.smim.2021.101485","volume":"52","author":"S Zhao","year":"2021","unstructured":"Zhao S, Peralta R, Avina-Ochoa N et al (2021) Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. Semin Immunol 52:101485. https:\/\/doi.org\/10.1016\/j.smim.2021.101485","journal-title":"Semin Immunol"},{"key":"2409_CR74","doi-asserted-by":"publisher","first-page":"116463","DOI":"10.1016\/j.celrep.2025.116463","volume":"44","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Tong H et al (2025) Metabolic regulation of immunity in the tumor microenvironment. Cell Rep 44:116463. https:\/\/doi.org\/10.1016\/j.celrep.2025.116463","journal-title":"Cell Rep"},{"key":"2409_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.2017-0519","volume":"24","author":"V Subbiah","year":"2019","unstructured":"Subbiah V, Kurzrock R (2019) The marriage between genomics and immunotherapy: mismatch meets its match. Oncologist 24:1\u20133. https:\/\/doi.org\/10.1634\/theoncologist.2017-0519","journal-title":"Oncologist"},{"key":"2409_CR76","doi-asserted-by":"publisher","first-page":"704397","DOI":"10.3389\/fonc.2021.704397","volume":"11","author":"M Abedalthagafi","year":"2021","unstructured":"Abedalthagafi M (2021) Editorial: Genomics and epigenomics of cancer immunotherapy: challenges and clinical implications. Front Oncol 11:704397. https:\/\/doi.org\/10.3389\/fonc.2021.704397","journal-title":"Front Oncol"},{"key":"2409_CR77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","volume":"52","author":"J Galon","year":"2020","unstructured":"Galon J, Bruni D (2020) Tumor immunology and tumor evolution: intertwined histories. Immunity 52:55\u201381. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.018","journal-title":"Immunity"},{"key":"2409_CR78","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","volume":"53","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Sakai C et al (2020) An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity 53:187\u2013203e8. https:\/\/doi.org\/10.1016\/j.immuni.2020.06.016","journal-title":"Immunity"},{"key":"2409_CR79","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1158\/0008-5472.CAN-19-0153","volume":"79","author":"K Krysan","year":"2019","unstructured":"Krysan K, Tran LM, Grimes BS et al (2019) The immune contexture associates with the genomic landscape in lung adenomatous premalignancy. Cancer Res 79:5022\u20135033. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0153","journal-title":"Cancer Res"},{"key":"2409_CR80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12967-022-03827-4","volume":"21","author":"S Han","year":"2023","unstructured":"Han S, Shi T, Liao Y et al (2023) Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer. J Transl Med 21:194. https:\/\/doi.org\/10.1186\/s12967-022-03827-4","journal-title":"J Transl Med"},{"key":"2409_CR81","doi-asserted-by":"publisher","first-page":"1558016","DOI":"10.3389\/fmed.2025.1558016","volume":"12","author":"D Kozakov","year":"2025","unstructured":"Kozakov D, Kobyliak N, Livshun S et al (2025) Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study. Front Med 12:1558016. https:\/\/doi.org\/10.3389\/fmed.2025.1558016","journal-title":"Front Med (Lausanne)"},{"key":"2409_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xiao X, Yi Y et al (2024) Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther 9:149. https:\/\/doi.org\/10.1038\/s41392-024-01848-7","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR83","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D et al (2020) Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol 12:674\u2013687. https:\/\/doi.org\/10.1093\/jmcb\/mjaa040","journal-title":"J Mol Cell Biol"},{"key":"2409_CR84","doi-asserted-by":"publisher","first-page":"e00054","DOI":"10.1042\/BSR20130065","volume":"33","author":"JL Silva","year":"2013","unstructured":"Silva JL, Rangel LP, Costa DCF et al (2013) Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep 33:e00054. https:\/\/doi.org\/10.1042\/BSR20130065","journal-title":"Biosci Rep"},{"key":"2409_CR85","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/jmcb\/mjz071","volume":"11","author":"Y Stein","year":"2019","unstructured":"Stein Y, Aloni-Grinstein R, Rotter V (2019) Mutant p53-a potential player in shaping the tumor-stroma crosstalk. J Mol Cell Biol 11:600\u2013604. https:\/\/doi.org\/10.1093\/jmcb\/mjz071","journal-title":"J Mol Cell Biol"},{"key":"2409_CR86","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2021.01.003","volume":"39","author":"M Ghosh","year":"2021","unstructured":"Ghosh M, Saha S, Bettke J et al (2021) Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell 39:494\u2013508e5. https:\/\/doi.org\/10.1016\/j.ccell.2021.01.003","journal-title":"Cancer Cell"},{"key":"2409_CR87","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.immuni.2025.06.005","volume":"58","author":"DB Mahat","year":"2025","unstructured":"Mahat DB, Kumra H, Castro SA et al (2025) Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Immunity 58:1688\u20131705e9. https:\/\/doi.org\/10.1016\/j.immuni.2025.06.005","journal-title":"Immunity"},{"key":"2409_CR88","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","volume":"23","author":"T Cooks","year":"2013","unstructured":"Cooks T, Pateras IS, Tarcic O et al (2013) Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23:634\u2013646. https:\/\/doi.org\/10.1016\/j.ccr.2013.03.022","journal-title":"Cancer Cell"},{"key":"2409_CR89","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1101\/gad.340976.120","volume":"34","author":"J Gencel-Augusto","year":"2020","unstructured":"Gencel-Augusto J, Lozano G (2020) p53 tetramerization: at the center of the dominant-negative effect of mutant p53. Genes Dev 34:1128\u20131146. https:\/\/doi.org\/10.1101\/gad.340976.120","journal-title":"Genes Dev"},{"key":"2409_CR90","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1073\/pnas.052713099","volume":"99","author":"A de Vries","year":"2002","unstructured":"de Vries A, Flores ER, Miranda B et al (2002) Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 99:2948\u20132953. https:\/\/doi.org\/10.1073\/pnas.052713099","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2409_CR91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525:206\u2013211. https:\/\/doi.org\/10.1038\/nature15251","journal-title":"Nature"},{"key":"2409_CR92","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"MP Kim","year":"2018","unstructured":"Kim MP, Lozano G (2018) Mutant p53 partners in crime. Cell Death Differ 25:161\u2013168. https:\/\/doi.org\/10.1038\/cdd.2017.185","journal-title":"Cell Death Differ"},{"key":"2409_CR93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trecan.2019.11.004","volume":"6","author":"Q Tang","year":"2020","unstructured":"Tang Q, Su Z, Gu W, Rustgi AK (2020) Mutant p53 on the path to metastasis. Trends Cancer 6:62\u201373. https:\/\/doi.org\/10.1016\/j.trecan.2019.11.004","journal-title":"Trends Cancer"},{"key":"2409_CR94","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.mocell.2025.100198","volume":"48","author":"KY Koo","year":"2025","unstructured":"Koo KY, Moon K, Song HS, Lee M-S (2025) Metabolic regulation by p53: implications for cancer therapy. Mol Cells 48:100198. https:\/\/doi.org\/10.1016\/j.mocell.2025.100198","journal-title":"Mol Cells"},{"key":"2409_CR95","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.jbior.2021.100839","volume":"83","author":"RM Loughran","year":"2022","unstructured":"Loughran RM, Emerling BM (2022) Mechanistic roles of mutant p53 governing lipid metabolism. Adv Biol Regul 83:100839. https:\/\/doi.org\/10.1016\/j.jbior.2021.100839","journal-title":"Adv Biol Regul"},{"key":"2409_CR96","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.molcel.2014.04.024","volume":"54","author":"G Zhou","year":"2014","unstructured":"Zhou G, Wang J, Zhao M et al (2014) Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54:960\u2013974. https:\/\/doi.org\/10.1016\/j.molcel.2014.04.024","journal-title":"Mol Cell"},{"key":"2409_CR97","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41467-025-57099-9","volume":"16","author":"J Liu","year":"2025","unstructured":"Liu J, Shen Y, Liu J et al (2025) Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nat Commun 16:1762. https:\/\/doi.org\/10.1038\/s41467-025-57099-9","journal-title":"Nat Commun"},{"key":"2409_CR98","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jcb.23400","volume":"113","author":"W Hanel","year":"2012","unstructured":"Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113:433\u2013439. https:\/\/doi.org\/10.1002\/jcb.23400","journal-title":"J Cell Biochem"},{"key":"2409_CR99","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41467-023-44239-2","volume":"15","author":"M Zhao","year":"2024","unstructured":"Zhao M, Wang T, Gleber-Netto FO et al (2024) Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15:180. https:\/\/doi.org\/10.1038\/s41467-023-44239-2","journal-title":"Nat Commun"},{"key":"2409_CR100","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-025-02549-5","volume":"11","author":"W Wang","year":"2026","unstructured":"Wang W, Liu X, Liu H et al (2026) p53: from understanding its structure to advances in therapeutic targeting. Signal Transduct Target Ther 11:121. https:\/\/doi.org\/10.1038\/s41392-025-02549-5","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR101","doi-asserted-by":"publisher","first-page":"595187","DOI":"10.3389\/fonc.2020.595187","volume":"10","author":"G Zhu","year":"2020","unstructured":"Zhu G, Pan C, Bei J-X et al (2020) Mutant p53 in cancer progression and targeted therapies. Front Oncol 10:595187. https:\/\/doi.org\/10.3389\/fonc.2020.595187","journal-title":"Front Oncol"},{"key":"2409_CR102","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE et al (2018) Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 50:1381\u20131387. https:\/\/doi.org\/10.1038\/s41588-018-0204-y","journal-title":"Nat Genet"},{"key":"2409_CR103","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler E, Shani O, Goldfeld G et al (2018) A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell 71:178\u2013190e8. https:\/\/doi.org\/10.1016\/j.molcel.2018.06.012","journal-title":"Mol Cell"},{"key":"2409_CR104","doi-asserted-by":"publisher","first-page":"a026039","DOI":"10.1101\/cshperspect.a026039","volume":"6","author":"SM Joruiz","year":"2016","unstructured":"Joruiz SM, Bourdon J-C (2016) p53 isoforms: key regulators of the cell fate decision. Cold Spring Harb Perspect Med 6:a026039. https:\/\/doi.org\/10.1101\/cshperspect.a026039","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2409_CR105","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo Y, Wu H, Wiesm\u00fcller L, Chen M (2024) Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell Death Dis 15:412. https:\/\/doi.org\/10.1038\/s41419-024-06783-7","journal-title":"Cell Death Dis"},{"key":"2409_CR106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ng0593-42","volume":"4","author":"D Dittmer","year":"1993","unstructured":"Dittmer D, Pati S, Zambetti G et al (1993) Gain of function mutations in p53. Nat Genet 4:42\u201346. https:\/\/doi.org\/10.1038\/ng0593-42","journal-title":"Nat Genet"},{"key":"2409_CR107","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ncb3380","volume":"18","author":"D Walerych","year":"2016","unstructured":"Walerych D, Lisek K, Sommaggio R et al (2016) Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol 18:897\u2013909. https:\/\/doi.org\/10.1038\/ncb3380","journal-title":"Nat Cell Biol"},{"key":"2409_CR108","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ et al (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25:154\u2013160. https:\/\/doi.org\/10.1038\/cdd.2017.180","journal-title":"Cell Death Differ"},{"key":"2409_CR109","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370. https:\/\/doi.org\/10.1016\/s0092-8674(00)81683-9","journal-title":"Cell"},{"key":"2409_CR110","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"2409_CR111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ccr.2006.08.013","volume":"10","author":"S Di Agostino","year":"2006","unstructured":"Di Agostino S, Strano S, Emiliozzi V et al (2006) Gain of function of mutant p53: the mutant p53\/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191\u2013202. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.013","journal-title":"Cancer Cell"},{"key":"2409_CR112","doi-asserted-by":"publisher","first-page":"e99599","DOI":"10.15252\/embj.201899599","volume":"38","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Ding L, Wang D et al (2019) EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J 38:e99599. https:\/\/doi.org\/10.15252\/embj.201899599","journal-title":"EMBO J"},{"key":"2409_CR113","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.cell.2009.12.016","volume":"139","author":"G Selivanova","year":"2009","unstructured":"Selivanova G, Ivaska J (2009) Integrins and mutant p53 on the road to metastasis. Cell 139:1220\u20131222. https:\/\/doi.org\/10.1016\/j.cell.2009.12.016","journal-title":"Cell"},{"key":"2409_CR114","doi-asserted-by":"publisher","first-page":"4684","DOI":"10.1158\/0008-5472.CAN-17-0393","volume":"77","author":"A Young","year":"2017","unstructured":"Young A, Ngiow SF, Madore J et al (2017) Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res 77:4684\u20134696. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0393","journal-title":"Cancer Res"},{"key":"2409_CR115","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","volume":"139","author":"PAJ Muller","year":"2009","unstructured":"Muller PAJ, Caswell PT, Doyle B et al (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139:1327\u20131341. https:\/\/doi.org\/10.1016\/j.cell.2009.11.026","journal-title":"Cell"},{"key":"2409_CR116","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1038\/ncomms3935","volume":"4","author":"C Zhang","year":"2013","unstructured":"Zhang C, Liu J, Liang Y et al (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4:2935. https:\/\/doi.org\/10.1038\/ncomms3935","journal-title":"Nat Commun"},{"key":"2409_CR117","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/ncomms8389","volume":"6","author":"M Kollareddy","year":"2015","unstructured":"Kollareddy M, Dimitrova E, Vallabhaneni KC et al (2015) Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat Commun 6:7389. https:\/\/doi.org\/10.1038\/ncomms8389","journal-title":"Nat Commun"},{"key":"2409_CR118","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41418-017-0026-y","volume":"25","author":"A Parrales","year":"2018","unstructured":"Parrales A, Thoenen E, Iwakuma T (2018) The interplay between mutant p53 and the mevalonate pathway. Cell Death Differ 25:460\u2013470. https:\/\/doi.org\/10.1038\/s41418-017-0026-y","journal-title":"Cell Death Differ"},{"key":"2409_CR119","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1101\/gad.263202.115","volume":"29","author":"NT Pfister","year":"2015","unstructured":"Pfister NT, Fomin V, Regunath K et al (2015) Mutant p53 cooperates with the SWI\/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev 29:1298\u20131315. https:\/\/doi.org\/10.1101\/gad.263202.115","journal-title":"Genes Dev"},{"key":"2409_CR120","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41420-025-02433-9","volume":"11","author":"R Benedetti","year":"2025","unstructured":"Benedetti R, Di Crosta M, Gilardini Montani MS et al (2025) Mutant p53 upregulates HDAC6 to resist ER stress and facilitates Ku70 deacetylation, which prevents its degradation and mitigates DNA damage in colon cancer cells. Cell Death Discov 11:162. https:\/\/doi.org\/10.1038\/s41420-025-02433-9","journal-title":"Cell Death Discov"},{"key":"2409_CR121","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/cdd.2011.71","volume":"18","author":"D Li","year":"2011","unstructured":"Li D, Marchenko ND, Moll UM (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18:1904\u20131913. https:\/\/doi.org\/10.1038\/cdd.2011.71","journal-title":"Cell Death Differ"},{"key":"2409_CR122","doi-asserted-by":"publisher","first-page":"100671","DOI":"10.1016\/j.drup.2019.100671","volume":"49","author":"X Cao","year":"2020","unstructured":"Cao X, Hou J, An Q et al (2020) Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updates 49:100671. https:\/\/doi.org\/10.1016\/j.drup.2019.100671","journal-title":"Drug Resist Updat"},{"key":"2409_CR123","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/cancers15020429","volume":"15","author":"S Nishikawa","year":"2023","unstructured":"Nishikawa S, Iwakuma T (2023) Drugs targeting p53 mutations with FDA approval and in clinical trials. Cancers 15:429. https:\/\/doi.org\/10.3390\/cancers15020429","journal-title":"Cancers (Basel)"},{"key":"2409_CR124","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1080\/15384101.2019.1688951","volume":"18","author":"Y Huang","year":"2019","unstructured":"Huang Y, Liu N, Liu J et al (2019) Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle 18:3442\u20133455. https:\/\/doi.org\/10.1080\/15384101.2019.1688951","journal-title":"Cell Cycle"},{"key":"2409_CR125","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H et al (2020) Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4:5681\u20135689. https:\/\/doi.org\/10.1182\/bloodadvances.2020003120","journal-title":"Blood Adv"},{"key":"2409_CR126","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/s41416-022-01971-8","volume":"127","author":"X Zhou","year":"2022","unstructured":"Zhou X, Santos GS, Zhan Y et al (2022) Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246. Br J Cancer 127:2060\u20132071. https:\/\/doi.org\/10.1038\/s41416-022-01971-8","journal-title":"Br J Cancer"},{"key":"2409_CR127","doi-asserted-by":"publisher","first-page":"217421","DOI":"10.1016\/j.canlet.2024.217421","volume":"611","author":"D Chai","year":"2025","unstructured":"Chai D, Wang X, Fan C et al (2025) Vaccines targeting p53 mutants elicit anti-tumor immunity. Cancer Lett 611:217421. https:\/\/doi.org\/10.1016\/j.canlet.2024.217421","journal-title":"Cancer Lett"},{"key":"2409_CR128","doi-asserted-by":"publisher","first-page":"1753215","DOI":"10.3389\/fimmu.2026.1753215","volume":"17","author":"L Liang","year":"2026","unstructured":"Liang L, Wang W (2026) The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. Front Immunol 17:1753215. https:\/\/doi.org\/10.3389\/fimmu.2026.1753215","journal-title":"Front Immunol"},{"key":"2409_CR129","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/hematology.2024000556","volume":"2024","author":"TN Wong","year":"2024","unstructured":"Wong TN, Link DC (2024) Are TP53 mutations all alike? Hematol Am Soc Hematol Educ Program 2024:321\u2013325. https:\/\/doi.org\/10.1182\/hematology.2024000556","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2409_CR130","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1038\/s41467-022-30481-7","volume":"13","author":"O Hassin","year":"2022","unstructured":"Hassin O, Nataraj NB, Shreberk-Shaked M et al (2022) Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat Commun 13:2800. https:\/\/doi.org\/10.1038\/s41467-022-30481-7","journal-title":"Nat Commun"},{"key":"2409_CR131","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ccell.2025.03.006","volume":"43","author":"SL Wang","year":"2025","unstructured":"Wang SL, Chan TA (2025) Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell 43:641\u2013664. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.006","journal-title":"Cancer Cell"},{"key":"2409_CR132","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W et al (2024) Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol 14:1483454. https:\/\/doi.org\/10.3389\/fonc.2024.1483454","journal-title":"Front Oncol"},{"key":"2409_CR133","doi-asserted-by":"publisher","first-page":"251513552311920","DOI":"10.1177\/25151355231192043","volume":"11","author":"AN Kamali","year":"2023","unstructured":"Kamali AN, Bautista JM, Eisenhut M, Hamedifar H (2023) Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands. Ther Adv Vaccines Immunother 11:25151355231192043. https:\/\/doi.org\/10.1177\/25151355231192043","journal-title":"Ther Adv Vaccines Immunother"},{"key":"2409_CR134","doi-asserted-by":"publisher","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","volume":"108","author":"MA Cortez","year":"2016","unstructured":"Cortez MA, Ivan C, Valdecanas D et al (2016) PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108:djv303. https:\/\/doi.org\/10.1093\/jnci\/djv303","journal-title":"J Natl Cancer Inst"},{"key":"2409_CR135","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"2409_CR136","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","volume":"41","author":"M Zhu","year":"2023","unstructured":"Zhu M, Kim J, Deng Q et al (2023) Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell 41:1731\u20131748e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.006","journal-title":"Cancer Cell"},{"key":"2409_CR137","doi-asserted-by":"publisher","first-page":"115320","DOI":"10.1016\/j.ejca.2025.115320","volume":"219","author":"K Steger","year":"2025","unstructured":"Steger K, Fiegl H, Feroz B et al (2025) Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer. Eur J Cancer 219:115320. https:\/\/doi.org\/10.1016\/j.ejca.2025.115320","journal-title":"Eur J Cancer"},{"key":"2409_CR138","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W (2024) Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 42:946\u2013967. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.009","journal-title":"Cancer Cell"},{"key":"2409_CR139","doi-asserted-by":"publisher","first-page":"e0179726","DOI":"10.1371\/journal.pone.0179726","volume":"12","author":"NO Siemers","year":"2017","unstructured":"Siemers NO, Holloway JL, Chang H et al (2017) Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE 12:e0179726. https:\/\/doi.org\/10.1371\/journal.pone.0179726","journal-title":"PLoS ONE"},{"key":"2409_CR140","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.tranon.2018.07.012","volume":"11","author":"Z Jiang","year":"2018","unstructured":"Jiang Z, Liu Z, Li M et al (2018) Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer. Transl Oncol 11:1171\u20131187. https:\/\/doi.org\/10.1016\/j.tranon.2018.07.012","journal-title":"Transl Oncol"},{"key":"2409_CR141","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N et al (2022) Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res 10:932\u2013946. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0040","journal-title":"Cancer Immunol Res"},{"key":"2409_CR142","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.3390\/cancers14163975","volume":"14","author":"J Vadakekolathu","year":"2022","unstructured":"Vadakekolathu J, Boocock DJ, Pandey K et al (2022) Multi-omic analysis of two common P53 mutations: proteins regulated by mutated P53 as potential targets for immunotherapy. Cancers 14:3975. https:\/\/doi.org\/10.3390\/cancers14163975","journal-title":"Cancers (Basel)"},{"key":"2409_CR143","doi-asserted-by":"publisher","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","volume":"371","author":"EH-C Hsiue","year":"2021","unstructured":"Hsiue EH-C, Wright KM, Douglass J et al (2021) Targeting a neoantigen derived from a common TP53 mutation. Science 371:eabc8697. https:\/\/doi.org\/10.1126\/science.abc8697","journal-title":"Science"},{"key":"2409_CR144","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-020-02764-9","volume":"70","author":"T Dao","year":"2021","unstructured":"Dao T, Klatt MG, Korontsvit T et al (2021) Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunol Immunother 70:1189\u20131202. https:\/\/doi.org\/10.1007\/s00262-020-02764-9","journal-title":"Cancer Immunol Immunother"},{"key":"2409_CR145","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta RG, Li F, Roszik J, Liz\u00e9e G (2021) Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov 11:1024\u20131039. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1575","journal-title":"Cancer Discov"},{"key":"2409_CR146","doi-asserted-by":"publisher","unstructured":"Anastasopoulou V, Schreiber H, Lee C-E et al (2025) Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology 14:2514041. https:\/\/doi.org\/10.1080\/2162402X.2025.2514041","DOI":"10.1080\/2162402X.2025.2514041"},{"key":"2409_CR147","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s41467-020-16755-y","volume":"11","author":"D Wu","year":"2020","unstructured":"Wu D, Gallagher DT, Gowthaman R et al (2020) Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen. Nat Commun 11:2908. https:\/\/doi.org\/10.1038\/s41467-020-16755-y","journal-title":"Nat Commun"},{"key":"2409_CR148","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","volume":"7","author":"W Lo","year":"2019","unstructured":"Lo W, Parkhurst M, Robbins PF et al (2019) Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res 7:534\u2013543. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0686","journal-title":"Cancer Immunol Res"},{"key":"2409_CR149","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-19-1874","volume":"26","author":"P Malekzadeh","year":"2020","unstructured":"Malekzadeh P, Yossef R, Cafri G et al (2020) Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin Cancer Res 26:1267\u20131276. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1874","journal-title":"Clin Cancer Res"},{"key":"2409_CR150","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC et al (2023) Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618:144\u2013150. https:\/\/doi.org\/10.1038\/s41586-023-06063-y","journal-title":"Nature"},{"key":"2409_CR151","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/cancers18010144","volume":"18","author":"A-C Wu","year":"2025","unstructured":"Wu A-C, Nakamura Y, Kiyotani K (2025) Advances in neoantigen-based cancer vaccines. Cancers 18:144. https:\/\/doi.org\/10.3390\/cancers18010144","journal-title":"Cancers (Basel)"},{"key":"2409_CR152","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13402-026-01199-1","volume":"49","author":"X Li","year":"2026","unstructured":"Li X, Jabbarzadeh Kaboli P, Roozitalab G et al (2026) Next-generation neoantigen mRNA vaccines: immuno-engineering strategies for precision cancer immunotherapy. Cell Oncol (Dordr) 49:72. https:\/\/doi.org\/10.1007\/s13402-026-01199-1","journal-title":"Cell Oncol (Dordr)"},{"key":"2409_CR153","doi-asserted-by":"publisher","first-page":"1267661","DOI":"10.3389\/fcell.2023.1267661","volume":"11","author":"S Zhou","year":"2023","unstructured":"Zhou S, Fan C, Zeng Z et al (2023) Corrigendum: Clinical and immunological effects of p53-targeting vaccines. Front Cell Dev Biol 11:1267661. https:\/\/doi.org\/10.3389\/fcell.2023.1267661","journal-title":"Front Cell Dev Biol"},{"key":"2409_CR154","doi-asserted-by":"publisher","first-page":"e1500671","DOI":"10.1080\/2162402X.2018.1500671","volume":"7","author":"J Quandt","year":"2018","unstructured":"Quandt J, Schlude C, Bartoschek M et al (2018) Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology 7:e1500671. https:\/\/doi.org\/10.1080\/2162402X.2018.1500671","journal-title":"Oncoimmunology"},{"key":"2409_CR155","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1038\/s41467-019-13305-z","volume":"10","author":"L Low","year":"2019","unstructured":"Low L, Goh A, Koh J et al (2019) Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nat Commun 10:5382. https:\/\/doi.org\/10.1038\/s41467-019-13305-z","journal-title":"Nat Commun"},{"key":"2409_CR156","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-21-0115","volume":"20","author":"Z Duan","year":"2021","unstructured":"Duan Z, Ho M (2021) T cell receptor mimic antibodies for cancer immunotherapy. Mol Cancer Ther 20:1533\u20131541. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0115","journal-title":"Mol Cancer Ther"},{"key":"2409_CR157","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/abt\/tbz001","volume":"2","author":"Y Xu","year":"2019","unstructured":"Xu Y, Salazar GT, Zhang N, An Z (2019) T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. Antib Ther 2:22\u201332. https:\/\/doi.org\/10.1093\/abt\/tbz001","journal-title":"Antib Ther"},{"key":"2409_CR158","doi-asserted-by":"publisher","first-page":"104507","DOI":"10.1016\/j.drudis.2025.104507","volume":"30","author":"EPW Meier","year":"2025","unstructured":"Meier EPW, Laustsen AH (2025) Advances in antibody-based strategies for targeting cancer-associated glycopeptide antigens. Drug Discov Today 30:104507. https:\/\/doi.org\/10.1016\/j.drudis.2025.104507","journal-title":"Drug Discovery Today"},{"key":"2409_CR159","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jcmgh.2020.10.012","volume":"11","author":"MS Martinho","year":"2020","unstructured":"Martinho MS, Nancarrow DJ, Lawrence TS et al (2020) Chaperones and ubiquitin ligases balance mutant p53 protein stability in esophageal and other digestive cancers. Cell Mol Gastroenterol Hepatol 11:449\u2013464. https:\/\/doi.org\/10.1016\/j.jcmgh.2020.10.012","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2409_CR160","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-022-00317-7","volume":"11","author":"J Li","year":"2022","unstructured":"Li J, Guo M, Chen L et al (2022) p53 amyloid aggregation in cancer: function, mechanism, and therapy. Exp Hematol Oncol 11:66. https:\/\/doi.org\/10.1186\/s40164-022-00317-7","journal-title":"Exp Hematol Oncol"},{"key":"2409_CR161","doi-asserted-by":"publisher","first-page":"e148141","DOI":"10.1172\/JCI148141","volume":"132","author":"A Ghosh","year":"2022","unstructured":"Ghosh A, Michels J, Mezzadra R et al (2022) Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. J Clin Invest 132:e148141. https:\/\/doi.org\/10.1172\/JCI148141","journal-title":"J Clin Invest"},{"key":"2409_CR162","doi-asserted-by":"publisher","first-page":"216766","DOI":"10.1016\/j.canlet.2024.216766","volume":"588","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Jaiswal S, Jakhmola V et al (2024) Potential role of p53 deregulation in modulating immune responses in human malignancies: a paradigm to develop immunotherapy. Cancer Lett 588:216766. https:\/\/doi.org\/10.1016\/j.canlet.2024.216766","journal-title":"Cancer Lett"},{"key":"2409_CR163","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3390\/cancers16173069","volume":"16","author":"C Wang","year":"2024","unstructured":"Wang C, Tan JYM, Chitkara N, Bhatt S (2024) TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications. Cancers 16:3069. https:\/\/doi.org\/10.3390\/cancers16173069","journal-title":"Cancers (Basel)"},{"key":"2409_CR164","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.molcel.2022.12.023","volume":"83","author":"M Ghosh","year":"2023","unstructured":"Ghosh M, Saha S, Li J et al (2023) p53 engages the cGAS\/STING cytosolic DNA sensing pathway for tumor suppression. Mol Cell 83:266\u2013280e6. https:\/\/doi.org\/10.1016\/j.molcel.2022.12.023","journal-title":"Mol Cell"},{"key":"2409_CR165","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","volume":"145","author":"CA Brady","year":"2011","unstructured":"Brady CA, Jiang D, Mello SS et al (2011) Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145:571\u2013583. https:\/\/doi.org\/10.1016\/j.cell.2011.03.035","journal-title":"Cell"},{"key":"2409_CR166","doi-asserted-by":"publisher","first-page":"113724","DOI":"10.1016\/j.celrep.2024.113724","volume":"43","author":"W Xia","year":"2024","unstructured":"Xia W, Jiang P (2024) p53 promotes antiviral innate immunity by driving hexosamine metabolism. Cell Rep 43:113724. https:\/\/doi.org\/10.1016\/j.celrep.2024.113724","journal-title":"Cell Rep"},{"key":"2409_CR167","doi-asserted-by":"publisher","first-page":"200768","DOI":"10.1016\/j.omton.2024.200768","volume":"32","author":"A Naik","year":"2024","unstructured":"Naik A, Lattab B, Qasem H, Decock J (2024) Cancer testis antigens: emerging therapeutic targets leveraging genomic instability in cancer. Mol Ther Oncol 32:200768. https:\/\/doi.org\/10.1016\/j.omton.2024.200768","journal-title":"Mol Ther Oncol"},{"key":"2409_CR168","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137\u20131146. https:\/\/doi.org\/10.1172\/JCI31405","journal-title":"J Clin Invest"},{"key":"2409_CR169","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1947601911409747","volume":"2","author":"AV Gudkov","year":"2011","unstructured":"Gudkov AV, Gurova KV, Komarova EA (2011) Inflammation and p53: a tale of two stresses. Genes Cancer 2:503\u2013516. https:\/\/doi.org\/10.1177\/1947601911409747","journal-title":"Genes Cancer"},{"key":"2409_CR170","doi-asserted-by":"publisher","first-page":"762651","DOI":"10.3389\/fcell.2021.762651","volume":"9","author":"D Shi","year":"2021","unstructured":"Shi D, Jiang P (2021) A different facet of p53 function: regulation of immunity and inflammation during tumor development. Front Cell Dev Biol 9:762651. https:\/\/doi.org\/10.3389\/fcell.2021.762651","journal-title":"Front Cell Dev Biol"},{"key":"2409_CR171","doi-asserted-by":"publisher","first-page":"e1001","DOI":"10.1002\/mgg3.1001","volume":"7","author":"M Behring","year":"2019","unstructured":"Behring M, Vazquez AI, Cui X et al (2019) Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages. Mol Genet Genomic Med 7:e1001. https:\/\/doi.org\/10.1002\/mgg3.1001","journal-title":"Mol Genet Genomic Med"},{"key":"2409_CR172","doi-asserted-by":"publisher","first-page":"109578","DOI":"10.1016\/j.celrep.2021.109578","volume":"36","author":"D Siolas","year":"2021","unstructured":"Siolas D, Vucic E, Kurz E et al (2021) Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy. Cell Rep 36:109578. https:\/\/doi.org\/10.1016\/j.celrep.2021.109578","journal-title":"Cell Rep"},{"key":"2409_CR173","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.celrep.2019.12.028","volume":"30","author":"J Blagih","year":"2020","unstructured":"Blagih J, Zani F, Chakravarty P et al (2020) Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep 30:481\u2013496e6. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.028","journal-title":"Cell Rep"},{"key":"2409_CR174","doi-asserted-by":"publisher","first-page":"9648","DOI":"10.3390\/ijms21249648","volume":"21","author":"E Pavlakis","year":"2020","unstructured":"Pavlakis E, Neumann M, Stiewe T (2020) Extracellular vesicles: messengers of p53 in tumor\u2013stroma communication and cancer metastasis. Int J Mol Sci 21:9648. https:\/\/doi.org\/10.3390\/ijms21249648","journal-title":"Int J Mol Sci"},{"key":"2409_CR175","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-024-02081-0","volume":"23","author":"M Bayat","year":"2024","unstructured":"Bayat M, Sadri Nahand J (2024) Exosomal miRNAs: the tumor\u2019s trojan horse in selective metastasis. Mol Cancer 23:167. https:\/\/doi.org\/10.1186\/s12943-024-02081-0","journal-title":"Mol Cancer"},{"key":"2409_CR176","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.3390\/cancers12123650","volume":"12","author":"P Ghahremanifard","year":"2020","unstructured":"Ghahremanifard P, Chanda A, Bonni S, Bose P (2020) TGF-\u03b2 mediated immune evasion in cancer\u2014spotlight on cancer-associated fibroblasts. Cancers (Basel) 12:3650. https:\/\/doi.org\/10.3390\/cancers12123650","journal-title":"Cancers (Basel)"},{"key":"2409_CR177","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.4161\/cc.21384","volume":"11","author":"C Guido","year":"2012","unstructured":"Guido C, Whitaker-Menezes D, Capparelli C et al (2012) Metabolic reprogramming of cancer-associated fibroblasts by TGF-\u03b2 drives tumor growth: connecting TGF-\u03b2 signaling with Warburg-like cancer metabolism and L-lactate production. Cell Cycle 11:3019\u20133035. https:\/\/doi.org\/10.4161\/cc.21384","journal-title":"Cell Cycle"},{"key":"2409_CR178","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12935-021-02396-8","volume":"21","author":"HE Marei","year":"2021","unstructured":"Marei HE, Althani A, Afifi N et al (2021) p53 signaling in cancer progression and therapy. Cancer Cell Int 21:703. https:\/\/doi.org\/10.1186\/s12935-021-02396-8","journal-title":"Cancer Cell Int"},{"key":"2409_CR179","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ebiom.2018.05.019","volume":"32","author":"W Xiao","year":"2018","unstructured":"Xiao W, Du N, Huang T et al (2018) TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma. EBioMedicine 32:119\u2013124. https:\/\/doi.org\/10.1016\/j.ebiom.2018.05.019","journal-title":"EBioMedicine"},{"key":"2409_CR180","doi-asserted-by":"publisher","first-page":"12438","DOI":"10.1002\/cam4.5953","volume":"12","author":"J-Y Kim","year":"2023","unstructured":"Kim J-Y, Jung J, Kim K-M et al (2023) TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors. Cancer Med 12:12438\u201312451. https:\/\/doi.org\/10.1002\/cam4.5953","journal-title":"Cancer Med"},{"key":"2409_CR181","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.3390\/ijms26146939","volume":"26","author":"A Yakobson","year":"2025","unstructured":"Yakobson A, Brenner R, Gothelf I et al (2025) Exploring the impact of TP53 mutation and wild-type status on the efficacy of immunotherapy in non-small cell lung cancer. Int J Mol Sci 26:6939. https:\/\/doi.org\/10.3390\/ijms26146939","journal-title":"Int J Mol Sci"},{"key":"2409_CR182","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/cancers14143382","volume":"14","author":"J Yu","year":"2022","unstructured":"Yu J, Fan Z, Zhou Z et al (2022) TP53 and LRP1B co-wild predicts improved survival for patients with LUSC receiving anti-PD-L1 immunotherapy. Cancers 14:3382. https:\/\/doi.org\/10.3390\/cancers14143382","journal-title":"Cancers (Basel)"},{"key":"2409_CR183","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-022-03557-7","volume":"20","author":"M Del Re","year":"2022","unstructured":"Del Re M, Crucitta S, Paolieri F et al (2022) The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. J Transl Med 20:371. https:\/\/doi.org\/10.1186\/s12967-022-03557-7","journal-title":"J Transl Med"},{"key":"2409_CR184","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s12250-021-00413-8","volume":"36","author":"H Dong","year":"2021","unstructured":"Dong H, Shu X, Xu Q et al (2021) Current status of human papillomavirus-related head and neck cancer: from viral genome to patient care. Virol Sin 36:1284\u20131302. https:\/\/doi.org\/10.1007\/s12250-021-00413-8","journal-title":"Virol Sin"},{"key":"2409_CR185","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/cancers17152590","volume":"17","author":"C-C Tsai","year":"2025","unstructured":"Tsai C-C, Hsu Y-C, Chu T-Y et al (2025) Immune evasion in head and neck squamous cell carcinoma: roles of cancer-associated fibroblasts, immune checkpoints, and TP53 mutations in the tumor microenvironment. Cancers 17:2590. https:\/\/doi.org\/10.3390\/cancers17152590","journal-title":"Cancers (Basel)"},{"key":"2409_CR186","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","volume":"30","author":"GJ Hanna","year":"2024","unstructured":"Hanna GJ, Dennis MJ, Scarfo N et al (2024) Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin Cancer Res 30:3329\u20133336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0590","journal-title":"Clin Cancer Res"},{"key":"2409_CR187","doi-asserted-by":"publisher","first-page":"5952836","DOI":"10.1155\/2019\/5952836","volume":"2019","author":"Z Liu","year":"2019","unstructured":"Liu Z, Jiang Z, Gao Y et al (2019) TP53 mutations promote immunogenic activity in breast cancer. J Oncol 2019:5952836. https:\/\/doi.org\/10.1155\/2019\/5952836","journal-title":"J Oncol"},{"key":"2409_CR188","doi-asserted-by":"publisher","first-page":"759154","DOI":"10.3389\/fcell.2021.759154","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Hao R, Guo Q et al (2021) TP53 mutation infers a poor prognosis and is correlated to immunocytes infiltration in breast cancer. Front Cell Dev Biol 9:759154. https:\/\/doi.org\/10.3389\/fcell.2021.759154","journal-title":"Front Cell Dev Biol"},{"key":"2409_CR189","doi-asserted-by":"publisher","first-page":"114826","DOI":"10.1016\/j.isci.2026.114826","volume":"29","author":"H Sang","year":"2026","unstructured":"Sang H, Zhao X (2026) JAK\/STAT-mediated regulation of PD-L1 expression in breast cancer: molecular mechanisms and implications for immunotherapy. iScience 29:114826. https:\/\/doi.org\/10.1016\/j.isci.2026.114826","journal-title":"iScience"},{"key":"2409_CR190","doi-asserted-by":"publisher","first-page":"1088455","DOI":"10.3389\/fgene.2023.1088455","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Liu T, Jiang J et al (2023) p53 mutation and deletion contribute to tumor immune evasion. Front Genet 14:1088455. https:\/\/doi.org\/10.3389\/fgene.2023.1088455","journal-title":"Front Genet"},{"key":"2409_CR191","doi-asserted-by":"publisher","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Cao L, Nguyen D, Lu H (2016) TP53 mutations in epithelial ovarian cancer. Transl Cancer Res 5:650\u2013663. https:\/\/doi.org\/10.21037\/tcr.2016.08.40","journal-title":"Transl Cancer Res"},{"key":"2409_CR192","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A et al (2023) Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 41:2436\u20132445. https:\/\/doi.org\/10.1200\/JCO.22.01900","journal-title":"J Clin Oncol"},{"key":"2409_CR193","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1200\/JCO.2019.37.15_suppl.5520","volume":"37","author":"DM O\u2019Malley","year":"2019","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ et al (2019) Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: final findings from the FORWARD II study. J Clin Oncol 37:5520\u20135520. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.5520","journal-title":"J Clin Oncol"},{"key":"2409_CR194","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-17-3401","volume":"24","author":"M Wartenberg","year":"2018","unstructured":"Wartenberg M, Cibin S, Zlobec I et al (2018) Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic\/predictive significance. Clin Cancer Res 24:4444\u20134454. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3401","journal-title":"Clin Cancer Res"},{"key":"2409_CR195","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/07853890.2018.1453168","volume":"50","author":"C Torres","year":"2018","unstructured":"Torres C, Grippo PJ (2018) Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 50:277\u2013287. https:\/\/doi.org\/10.1080\/07853890.2018.1453168","journal-title":"Ann Med"},{"key":"2409_CR196","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47\u201352. https:\/\/doi.org\/10.1038\/nature16965","journal-title":"Nature"},{"key":"2409_CR197","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00018-025-05945-w","volume":"83","author":"J-H Shin","year":"2025","unstructured":"Shin J-H, Kim H-R, Roe J-S (2025) Mutant p53 regulates reversible subtype plasticity in pancreatic cancer. Cell Mol Life Sci 83:31. https:\/\/doi.org\/10.1007\/s00018-025-05945-w","journal-title":"Cell Mol Life Sci"},{"key":"2409_CR198","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41392-025-02499-y","volume":"11","author":"E Rozengurt","year":"2026","unstructured":"Rozengurt E, Eibl G (2026) Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies. Signal Transduct Target Ther 11:6. https:\/\/doi.org\/10.1038\/s41392-025-02499-y","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR199","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G et al (2021) Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol 39:1584\u20131594. https:\/\/doi.org\/10.1200\/JCO.20.02341","journal-title":"J Clin Oncol"},{"key":"2409_CR200","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"2409_CR201","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.3390\/cancers17243984","volume":"17","author":"M Specchia","year":"2025","unstructured":"Specchia M, Drittone D, Mazzotti E, Mazzuca F (2025) Can TP53, TMB and TME expand the immunotherapy benefit in metastatic colorectal cancer? Cancers 17:3984. https:\/\/doi.org\/10.3390\/cancers17243984","journal-title":"Cancers (Basel)"},{"key":"2409_CR202","doi-asserted-by":"publisher","first-page":"e16014","DOI":"10.1200\/JCO.2020.38.15_suppl.e16014","volume":"38","author":"Z Lu","year":"2020","unstructured":"Lu Z, Shen L, Zhang H et al (2020) Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer. J Clin Oncol 38:e16014\u2013e16014. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e16014","journal-title":"J Clin Oncol"},{"key":"2409_CR203","doi-asserted-by":"publisher","first-page":"794183","DOI":"10.3389\/fonc.2021.794183","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yan X, Zhang F et al (2022) TCR-T immunotherapy: the challenges and solutions. Front Oncol 11:794183. https:\/\/doi.org\/10.3389\/fonc.2021.794183","journal-title":"Front Oncol"},{"key":"2409_CR204","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13000-017-0605-8","volume":"12","author":"M Zhang","year":"2017","unstructured":"Zhang M, Zhuang G, Sun X et al (2017) TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol 12:16. https:\/\/doi.org\/10.1186\/s13000-017-0605-8","journal-title":"Diagn Pathol"},{"key":"2409_CR205","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/tlcr-2025-1030","volume":"15","author":"Y Yang","year":"2026","unstructured":"Yang Y, Zhuo Z, Liu C et al (2026) TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profiling. Transl Lung Cancer Res 15:10. https:\/\/doi.org\/10.21037\/tlcr-2025-1030","journal-title":"Transl Lung Cancer Res"},{"key":"2409_CR206","doi-asserted-by":"publisher","unstructured":"Hu C, Zhao L, Liu W et al (2021) Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003773","DOI":"10.1136\/jitc-2021-003773"},{"key":"2409_CR207","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L (2021) KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther 6:386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR208","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.3390\/cancers15123076","volume":"15","author":"N Otegui","year":"2023","unstructured":"Otegui N, Houry M, Arozarena I et al (2023) Cancer cell-intrinsic alterations associated with an immunosuppressive tumor microenvironment and resistance to immunotherapy in lung cancer. Cancers 15:3076. https:\/\/doi.org\/10.3390\/cancers15123076","journal-title":"Cancers (Basel)"},{"key":"2409_CR209","doi-asserted-by":"publisher","first-page":"175883592110069","DOI":"10.1177\/17588359211006950","volume":"13","author":"M Gu","year":"2021","unstructured":"Gu M, Xu T, Chang P (2021) KRAS\/LKB1 and KRAS\/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Ther Adv Med Oncol 13:17588359211006950. https:\/\/doi.org\/10.1177\/17588359211006950","journal-title":"Ther Adv Med Oncol"},{"key":"2409_CR210","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"Z-Y Dong","year":"2017","unstructured":"Dong Z-Y, Zhong W-Z, Zhang X-C et al (2017) Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res 23:3012\u20133024. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554","journal-title":"Clin Cancer Res"},{"key":"2409_CR211","doi-asserted-by":"publisher","unstructured":"Frost N, Kollmeier J, Vollbrecht C et al (2021) KRASG12C\/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (\u2265\u200950%) lung adenocarcinoma. Transl Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr-20-958","DOI":"10.21037\/tlcr-20-958"},{"key":"2409_CR212","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41419-026-08607-2","volume":"17","author":"Q Li","year":"2026","unstructured":"Li Q, Song Q, Ma L et al (2026) The cGAS-STING pathway in cancer: friend or foe. Cell Death Dis 17:374. https:\/\/doi.org\/10.1038\/s41419-026-08607-2","journal-title":"Cell Death Dis"},{"key":"2409_CR213","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ymthe.2022.01.044","volume":"30","author":"Z-J Long","year":"2022","unstructured":"Long Z-J, Wang J-D, Xu J-Q et al (2022) cGAS\/STING cross-talks with cell cycle and potentiates cancer immunotherapy. Mol Ther 30:1006\u20131017. https:\/\/doi.org\/10.1016\/j.ymthe.2022.01.044","journal-title":"Mol Ther"},{"key":"2409_CR214","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s42003-025-09050-3","volume":"8","author":"K Liu","year":"2025","unstructured":"Liu K, Garan LAW, Lin F-T, Lin W-C (2025) Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition. Commun Biol 8:1522. https:\/\/doi.org\/10.1038\/s42003-025-09050-3","journal-title":"Commun Biol"},{"key":"2409_CR215","doi-asserted-by":"publisher","first-page":"188447","DOI":"10.1016\/j.bbcan.2020.188447","volume":"1874","author":"DY Lizardo","year":"2020","unstructured":"Lizardo DY, Kuang C, Hao S et al (2020) Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer 1874:188447. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188447","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2409_CR216","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008. https:\/\/doi.org\/10.1101\/cshperspect.a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2409_CR217","doi-asserted-by":"publisher","first-page":"E292","DOI":"10.1002\/lary.25915","volume":"126","author":"A Scheel","year":"2016","unstructured":"Scheel A, Bellile E, McHugh JB et al (2016) Classification of TP53 mutations and HPV predict survival in advanced larynx cancer. Laryngoscope 126:E292\u2013E299. https:\/\/doi.org\/10.1002\/lary.25915","journal-title":"Laryngoscope"},{"key":"2409_CR218","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3390\/cancers17152590","volume":"17","author":"C-C Tsai","year":"2025","unstructured":"Tsai C-C, Hsu Y-C, Chu T-Y et al (2025) Immune evasion in head and neck squamous cell carcinoma: roles of cancer-associated fibroblasts, immune checkpoints, and TP53 mutations in the tumor microenvironment. Cancers 17:2590. https:\/\/doi.org\/10.3390\/cancers17152590","journal-title":"Cancers"},{"key":"2409_CR219","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.bbrep.2022.101359","volume":"32","author":"W Kong","year":"2022","unstructured":"Kong W, Han Y, Gu H et al (2022) TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC. Biochem Biophys Rep 32:101359. https:\/\/doi.org\/10.1016\/j.bbrep.2022.101359","journal-title":"Biochem Biophys Rep"},{"key":"2409_CR220","doi-asserted-by":"publisher","first-page":"63","DOI":"10.20517\/cdr.2025.153","volume":"8","author":"W Zhao","year":"2025","unstructured":"Zhao W, Luo Q, Yuan B et al (2025) Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies. Cancer Drug Resist 8:63. https:\/\/doi.org\/10.20517\/cdr.2025.153","journal-title":"Cancer Drug Resist"},{"key":"2409_CR221","doi-asserted-by":"publisher","first-page":"107998","DOI":"10.1016\/j.oraloncology.2026.107998","volume":"178","author":"C Griffin","year":"2026","unstructured":"Griffin C, Donovan ML, Lawler C et al (2026) Tertiary lymphoid structures in head and neck squamous cell carcinoma as predictors of response to immunotherapy. Oral Oncol 178:107998. https:\/\/doi.org\/10.1016\/j.oraloncology.2026.107998","journal-title":"Oral Oncol"},{"key":"2409_CR222","doi-asserted-by":"publisher","unstructured":"Zhang L, Ren S, Lan T et al (2025) Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma. Oncoimmunology 14:2528109. https:\/\/doi.org\/10.1080\/2162402X.2025.2528109","DOI":"10.1080\/2162402X.2025.2528109"},{"key":"2409_CR223","doi-asserted-by":"publisher","first-page":"101629","DOI":"10.1016\/j.tranon.2023.101629","volume":"29","author":"H-P Liu","year":"2023","unstructured":"Liu H-P, Jia W, Kadeerhan G et al (2023) Individualized prognosis stratification in muscle invasive bladder cancer: a pairwise TP53-derived transcriptome signature. Transl Oncol 29:101629. https:\/\/doi.org\/10.1016\/j.tranon.2023.101629","journal-title":"Translational Oncol"},{"key":"2409_CR224","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","volume":"72","author":"W Choi","year":"2017","unstructured":"Choi W, Ochoa A, McConkey DJ et al (2017) Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome Atlas dataset. Eur Urol 72:354\u2013365. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.010","journal-title":"Eur Urol"},{"key":"2409_CR225","doi-asserted-by":"publisher","first-page":"1550341","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2018","unstructured":"Boichard A, Pham TV, Yeerna H et al (2018) APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology 8:1550341. https:\/\/doi.org\/10.1080\/2162402X.2018.1550341","journal-title":"Oncoimmunology"},{"key":"2409_CR226","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/curroncol29030117","volume":"29","author":"IA Voutsadakis","year":"2022","unstructured":"Voutsadakis IA (2022) Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr Oncol 29:1390\u20131407. https:\/\/doi.org\/10.3390\/curroncol29030117","journal-title":"Curr Oncol"},{"key":"2409_CR227","doi-asserted-by":"publisher","first-page":"816706","DOI":"10.3389\/fonc.2022.816706","volume":"12","author":"D Natesan","year":"2022","unstructured":"Natesan D, Zhang L, Martell HJ et al (2022) APOBEC mutational signature and tumor mutational burden as predictors of clinical outcomes and treatment response in patients with advanced urothelial cancer. Front Oncol 12:816706. https:\/\/doi.org\/10.3389\/fonc.2022.816706","journal-title":"Front Oncol"},{"key":"2409_CR228","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41467-025-56462-0","volume":"16","author":"LM Boll","year":"2025","unstructured":"Boll LM, V\u00e1zquez M, de Oca S, Camarena ME et al (2025) Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nat Commun 16:1213. https:\/\/doi.org\/10.1038\/s41467-025-56462-0","journal-title":"Nat Commun"},{"key":"2409_CR229","doi-asserted-by":"publisher","unstructured":"Madkhali OA, Moni SS, Almoshari Y et al (2025) Dual role of CXCL10 in cancer progression: implications for immunotherapy and targeted treatment. Cancer Biol Ther 26:2538962. https:\/\/doi.org\/10.1080\/15384047.2025.2538962","DOI":"10.1080\/15384047.2025.2538962"},{"key":"2409_CR230","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12672-024-00982-6","volume":"15","author":"T Yin","year":"2024","unstructured":"Yin T, Mou S, Zhang H et al (2024) CXCL10 could be a prognostic and immunological biomarker in bladder cancer. Discov Oncol 15:148. https:\/\/doi.org\/10.1007\/s12672-024-00982-6","journal-title":"Discov Oncol"},{"key":"2409_CR231","doi-asserted-by":"publisher","first-page":"1002304","DOI":"10.37349\/etat.2025.1002304","volume":"6","author":"A Di Spirito","year":"2025","unstructured":"Di Spirito A, Balkhi S, Vivona V, Mortara L (2025) Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies. Explor Target Antitumor Ther 6:1002304. https:\/\/doi.org\/10.37349\/etat.2025.1002304","journal-title":"Explor Target Antitumor Ther"},{"key":"2409_CR232","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","volume":"23","author":"JL Green","year":"2021","unstructured":"Green JL, Osterhout RE, Klova AL et al (2021) Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Mol Ther Oncolytics 23:547\u2013559. https:\/\/doi.org\/10.1016\/j.omto.2021.11.006","journal-title":"Mol Therapy - Oncolytics"},{"key":"2409_CR233","doi-asserted-by":"publisher","first-page":"e1577125","DOI":"10.1080\/2162402X.2019.1577125","volume":"8","author":"D Plote","year":"2019","unstructured":"Plote D, Choi W, Mokkapati S et al (2019) Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology 8:e1577125. https:\/\/doi.org\/10.1080\/2162402X.2019.1577125","journal-title":"Oncoimmunology"},{"key":"2409_CR234","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-642-78771-3_10","volume":"139","author":"J Weiss","year":"1995","unstructured":"Weiss J, Heine M, Arden KC et al (1995) Mutation and expression of TP53 in malignant melanomas. Recent Res Cancer Res 139:137\u2013154. https:\/\/doi.org\/10.1007\/978-3-642-78771-3_10","journal-title":"Recent Results Cancer Res"},{"key":"2409_CR235","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2017.09.004","volume":"52","author":"ML Axelrod","year":"2018","unstructured":"Axelrod ML, Johnson DB, Balko JM (2018) Emerging biomarkers for cancer immunotherapy in melanoma. Semin Cancer Biol 52:207\u2013215. https:\/\/doi.org\/10.1016\/j.semcancer.2017.09.004","journal-title":"Semin Cancer Biol"},{"key":"2409_CR236","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/biomedicines13010098","volume":"13","author":"T Timis","year":"2025","unstructured":"Timis T, Buruiana S, Dima D et al (2025) Advances in cell and immune therapies for melanoma. Biomedicines 13:98. https:\/\/doi.org\/10.3390\/biomedicines13010098","journal-title":"Biomedicines"},{"key":"2409_CR237","doi-asserted-by":"publisher","unstructured":"Liang L, Wang W (2026) The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. Front Immunol 17:1753215. https:\/\/doi.org\/10.3389\/fimmu.2026.1753215","DOI":"10.3389\/fimmu.2026.1753215"},{"key":"2409_CR238","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/cancers13071648","volume":"13","author":"JB Loureiro","year":"2021","unstructured":"Loureiro JB, Raimundo L, Calheiros J et al (2021) Targeting p53 for melanoma treatment: counteracting tumour proliferation, dissemination and therapeutic resistance. Cancers 13:1648. https:\/\/doi.org\/10.3390\/cancers13071648","journal-title":"Cancers (Basel)"},{"key":"2409_CR239","doi-asserted-by":"publisher","first-page":"114913","DOI":"10.5306\/wjco.v17.i1.114913","volume":"17","author":"MMGL Oliveira","year":"2026","unstructured":"Oliveira MMGL, Lemos CS, Braz\u00e3o MLS et al (2026) Immune landscape of melanoma: tumor microenvironment, resistance mechanisms, and predictive biomarkers. World J Clin Oncol 17:114913. https:\/\/doi.org\/10.5306\/wjco.v17.i1.114913","journal-title":"World J Clin Oncol"},{"key":"2409_CR240","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41698-022-00303-6","volume":"6","author":"ZI Mitri","year":"2022","unstructured":"Mitri ZI, Abuhadra N, Goodyear SM et al (2022) Impact of TP53 mutations in triple negative breast cancer. NPJ Precis Oncol 6:64. https:\/\/doi.org\/10.1038\/s41698-022-00303-6","journal-title":"NPJ Precis Oncol"},{"key":"2409_CR241","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","volume":"18","author":"Z Sporikova","year":"2018","unstructured":"Sporikova Z, Koudelakova V, Trojanec R, Hajduch M (2018) Genetic markers in triple-negative breast cancer. Clin Breast Cancer 18:e841\u2013e850. https:\/\/doi.org\/10.1016\/j.clbc.2018.07.023","journal-title":"Clin Breast Cancer"},{"key":"2409_CR242","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/jacsau.3c00099","volume":"3","author":"T Tian","year":"2023","unstructured":"Tian T, Zhao B, Wei H et al (2023) Programing immunogenic cell death in breast tumors with designer DNA frameworks. JACS Au 3:1241\u20131249. https:\/\/doi.org\/10.1021\/jacsau.3c00099","journal-title":"JACS Au"},{"key":"2409_CR243","doi-asserted-by":"publisher","first-page":"1572195","DOI":"10.3389\/fphar.2025.1572195","volume":"16","author":"C Li","year":"2025","unstructured":"Li C, Qi X, Yan M (2025) Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications. Front Pharmacol 16:1572195. https:\/\/doi.org\/10.3389\/fphar.2025.1572195","journal-title":"Front Pharmacol"},{"key":"2409_CR244","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1479-5876-3-34","volume":"3","author":"H Nijman","year":"2005","unstructured":"Nijman H, Lambeck A, van der Burg S et al (2005) Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med 3:34. https:\/\/doi.org\/10.1186\/1479-5876-3-34","journal-title":"J Transl Med"},{"key":"2409_CR245","doi-asserted-by":"publisher","unstructured":"Chatterjee R, Simoni-Nieves A, Truong A et al (2025) Sensitizing immune-refractory ovarian tumors via p53 mutation-tailored immunotherapy. bioRxiv. https:\/\/doi.org\/10.1101\/2025.06.23.661120","DOI":"10.1101\/2025.06.23.661120"},{"key":"2409_CR246","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.xcrm.2023.101092","volume":"4","author":"H Lu","year":"2023","unstructured":"Lu H, Lou H, Wengert G et al (2023) Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep Med 4:101092. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101092","journal-title":"Cell Rep Med"},{"key":"2409_CR247","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3390\/cancers11070894","volume":"11","author":"P Gupta","year":"2019","unstructured":"Gupta P, Chen C, Chaluvally-Raghavan P, Pradeep S (2019) B cells as an immune-regulatory signature in ovarian cancer. Cancers 11:894. https:\/\/doi.org\/10.3390\/cancers11070894","journal-title":"Cancers (Basel)"},{"key":"2409_CR248","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM et al (2022) TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov 12:2516\u20132529. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0332","journal-title":"Cancer Discov"},{"key":"2409_CR249","doi-asserted-by":"publisher","first-page":"e70164","DOI":"10.1002\/hem3.70164","volume":"9","author":"DA Sallman","year":"2025","unstructured":"Sallman DA, Komrokji RS, Dezern AE et al (2025) Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS\/AML. HemaSphere 9:e70164. https:\/\/doi.org\/10.1002\/hem3.70164","journal-title":"Hemasphere"},{"key":"2409_CR250","doi-asserted-by":"publisher","first-page":"e2500296","DOI":"10.1002\/advs.202500296","volume":"12","author":"L Gehrcken","year":"2025","unstructured":"Gehrcken L, Deben C, Smits E, Van Audenaerde JRM (2025) STING agonists and how to reach their full potential in cancer immunotherapy. Adv Sci 12:e2500296. https:\/\/doi.org\/10.1002\/advs.202500296","journal-title":"Adv Sci (Weinh)"},{"key":"2409_CR251","doi-asserted-by":"publisher","first-page":"1657374","DOI":"10.1080\/2162402X.2019.1657374","volume":"8","author":"R Tripathi","year":"2019","unstructured":"Tripathi R, Modur V, Senovilla L et al (2019) Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. Oncoimmunology 8:1657374. https:\/\/doi.org\/10.1080\/2162402X.2019.1657374","journal-title":"Oncoimmunology"},{"key":"2409_CR252","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-2532","author":"KC Murphy","year":"2025","unstructured":"Murphy KC, DeMarco KD, Zhou L et al (2025) MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-2532","journal-title":"Cancer Res"},{"key":"2409_CR253","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov 22:127\u2013144. https:\/\/doi.org\/10.1038\/s41573-022-00571-8","journal-title":"Nat Rev Drug Discov"},{"key":"2409_CR254","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","volume":"15","author":"JMR Lambert","year":"2009","unstructured":"Lambert JMR, Gorzov P, Veprintsev DB et al (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376\u2013388. https:\/\/doi.org\/10.1016\/j.ccr.2009.03.003","journal-title":"Cancer Cell"},{"key":"2409_CR255","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/cancers9120172","volume":"9","author":"A Perdrix","year":"2017","unstructured":"Perdrix A, Najem A, Saussez S et al (2017) PRIMA-1 and PRIMA-1Met (APR-246): from mutant\/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies. Cancers 9:172. https:\/\/doi.org\/10.3390\/cancers9120172","journal-title":"Cancers (Basel)"},{"key":"2409_CR256","doi-asserted-by":"publisher","first-page":"hzv006","DOI":"10.1093\/biohorizons\/hzv006","volume":"8","author":"EJ Lewis","year":"2015","unstructured":"Lewis EJ (2015) PRIMA-1 as a cancer therapy restoring mutant p53: a review. Bioscience Horizons 8:hzv006. https:\/\/doi.org\/10.1093\/biohorizons\/hzv006","journal-title":"Bioscience Horizons"},{"key":"2409_CR257","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","volume":"9","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J (2018) APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis 9:439. https:\/\/doi.org\/10.1038\/s41419-018-0463-7","journal-title":"Cell Death Dis"},{"key":"2409_CR258","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41418-023-01122-3","volume":"30","author":"Z Wang","year":"2023","unstructured":"Wang Z, Hu H, Heitink L et al (2023) The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death Differ 30:1033\u20131046. https:\/\/doi.org\/10.1038\/s41418-023-01122-3","journal-title":"Cell Death Differ"},{"key":"2409_CR259","doi-asserted-by":"publisher","first-page":"e10852","DOI":"10.15252\/emmm.201910852","volume":"13","author":"S Ceder","year":"2021","unstructured":"Ceder S, Eriksson SE, Cheteh EH et al (2021) A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Mol Med 13:e10852. https:\/\/doi.org\/10.15252\/emmm.201910852","journal-title":"EMBO Mol Med"},{"key":"2409_CR260","doi-asserted-by":"publisher","first-page":"100573","DOI":"10.1016\/j.esmoop.2022.100573","volume":"7","author":"H Park","year":"2022","unstructured":"Park H, Shapiro GI, Gao X et al (2022) Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open 7:100573. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100573","journal-title":"ESMO Open"},{"key":"2409_CR261","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2352-3026(22)00265-4","volume":"10","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G (2023) Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations. Lancet Haematol 10:e71\u2013e78. https:\/\/doi.org\/10.1016\/S2352-3026(22)00265-4","journal-title":"Lancet Haematol"},{"key":"2409_CR262","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2159-8290.CD-22-0381","volume":"13","author":"KZ Guiley","year":"2023","unstructured":"Guiley KZ, Shokat KM (2023) A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discov 13:56\u201369. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0381","journal-title":"Cancer Discov"},{"key":"2409_CR263","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tips.2023.02.007","volume":"44","author":"MMJ Fallatah","year":"2023","unstructured":"Fallatah MMJ, Law FV, Chow WA, Kaiser P (2023) Small-molecule correctors and stabilizers to target p53. Trends Pharmacol Sci 44:274\u2013289. https:\/\/doi.org\/10.1016\/j.tips.2023.02.007","journal-title":"Trends Pharmacol Sci"},{"key":"2409_CR264","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.compbiolchem.2019.05.005","volume":"80","author":"V Raghavan","year":"2019","unstructured":"Raghavan V, Agrahari M, Gowda DK (2019) Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics. Comput Biol Chem 80:398\u2013408. https:\/\/doi.org\/10.1016\/j.compbiolchem.2019.05.005","journal-title":"Comput Biol Chem"},{"key":"2409_CR265","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1073\/pnas.0805326105","volume":"105","author":"FM Boeckler","year":"2008","unstructured":"Boeckler FM, Joerger AC, Jaggi G et al (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360\u201310365. https:\/\/doi.org\/10.1073\/pnas.0805326105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2409_CR266","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1093\/nar\/gkt305","volume":"41","author":"X Liu","year":"2013","unstructured":"Liu X, Wilcken R, Joerger AC et al (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034\u20136044. https:\/\/doi.org\/10.1093\/nar\/gkt305","journal-title":"Nucleic Acids Res"},{"key":"2409_CR267","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10549-019-05435-1","volume":"179","author":"NC Synnott","year":"2020","unstructured":"Synnott NC, O\u2019Connell D, Crown J, Duffy MJ (2020) COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. Breast Cancer Res Treat 179:47\u201356. https:\/\/doi.org\/10.1007\/s10549-019-05435-1","journal-title":"Breast Cancer Res Treat"},{"key":"2409_CR268","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/21655979.2020.1729927","volume":"11","author":"Y Guo","year":"2020","unstructured":"Guo Y, Zhu X, Sun X (2020) COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203. Bioengineered 11:201\u2013208. https:\/\/doi.org\/10.1080\/21655979.2020.1729927","journal-title":"Bioengineered"},{"key":"2409_CR269","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","volume":"286","author":"BA Foster","year":"1999","unstructured":"Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507\u20132510. https:\/\/doi.org\/10.1126\/science.286.5449.2507","journal-title":"Science"},{"key":"2409_CR270","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/sj.onc.1205362","volume":"21","author":"TM Rippin","year":"2002","unstructured":"Rippin TM, Bykov VJN, Freund SMV et al (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119\u20132129. https:\/\/doi.org\/10.1038\/sj.onc.1205362","journal-title":"Oncogene"},{"key":"2409_CR271","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1006\/excr.2002.5526","volume":"276","author":"Y Luu","year":"2002","unstructured":"Luu Y, Bush J, Cheung K-J, Li G (2002) The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax\/mitochondrial\/caspase-9 pathway. Exp Cell Res 276:214\u2013222. https:\/\/doi.org\/10.1006\/excr.2002.5526","journal-title":"Exp Cell Res"},{"key":"2409_CR272","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/MCB.23.6.2171-2181.2003","volume":"23","author":"W Wang","year":"2003","unstructured":"Wang W, Takimoto R, Rastinejad F, El-Deiry WS (2003) Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23:2171\u20132181. https:\/\/doi.org\/10.1128\/MCB.23.6.2171-2181.2003","journal-title":"Mol Cell Biol"},{"key":"2409_CR273","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1038\/sj.onc.1207198","volume":"22","author":"J Wischhusen","year":"2003","unstructured":"Wischhusen J, Naumann U, Ohgaki H et al (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233\u20138245. https:\/\/doi.org\/10.1038\/sj.onc.1207198","journal-title":"Oncogene"},{"key":"2409_CR274","doi-asserted-by":"publisher","first-page":"45887","DOI":"10.1074\/jbc.M401854200","volume":"279","author":"MJ Demma","year":"2004","unstructured":"Demma MJ, Wong S, Maxwell E, Dasmahapatra B (2004) CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 279:45887\u201345896. https:\/\/doi.org\/10.1074\/jbc.M401854200","journal-title":"J Biol Chem"},{"key":"2409_CR275","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","volume":"39","author":"S Chen","year":"2021","unstructured":"Chen S, Wu J-L, Liang Y et al (2021) Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 39:225\u2013239e8. https:\/\/doi.org\/10.1016\/j.ccell.2020.11.013","journal-title":"Cancer Cell"},{"key":"2409_CR276","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.4155\/fmc-2019-0181","volume":"11","author":"MR Bauer","year":"2019","unstructured":"Bauer MR, Jones RN, Tareque RK et al (2019) A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C. Future Med Chem 11:2491\u20132504. https:\/\/doi.org\/10.4155\/fmc-2019-0181","journal-title":"Future Med Chem"},{"key":"2409_CR277","doi-asserted-by":"publisher","first-page":"116121","DOI":"10.1016\/j.ejmech.2024.116121","volume":"265","author":"Y Huang","year":"2024","unstructured":"Huang Y, Jiao Z, Fu Y et al (2024) An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53. Eur J Med Chem 265:116121. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116121","journal-title":"Eur J Med Chem"},{"key":"2409_CR278","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1038\/leu.2009.180","volume":"23","author":"E Drakos","year":"2009","unstructured":"Drakos E, Atsaves V, Schlette E et al (2009) The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 23:2290\u20132299. https:\/\/doi.org\/10.1038\/leu.2009.180","journal-title":"Leukemia"},{"key":"2409_CR279","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41419-025-07770-2","volume":"16","author":"G Tang","year":"2025","unstructured":"Tang G, Cao X, Chen J et al (2025) Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS\/p-p38\/NOXA\/caspase-3\/GSDME axis. Cell Death Dis 16:452. https:\/\/doi.org\/10.1038\/s41419-025-07770-2","journal-title":"Cell Death Dis"},{"key":"2409_CR280","doi-asserted-by":"publisher","first-page":"12609","DOI":"10.1038\/ncomms12609","volume":"7","author":"J Jung","year":"2016","unstructured":"Jung J, Lee JS, Dickson MA et al (2016) TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun 7:12609. https:\/\/doi.org\/10.1038\/ncomms12609","journal-title":"Nat Commun"},{"key":"2409_CR281","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1038\/cddis.2017.108","volume":"8","author":"EM Alexandrova","year":"2017","unstructured":"Alexandrova EM, Xu S, Moll UM (2017) Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner. Cell Death Dis 8:e2683. https:\/\/doi.org\/10.1038\/cddis.2017.108","journal-title":"Cell Death Dis"},{"key":"2409_CR282","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1038\/cddis.2013.488","volume":"4","author":"J-L Roh","year":"2013","unstructured":"Roh J-L, Kim EH, Park HB, Park JY (2013) The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. Cell Death Dis 4:e956. https:\/\/doi.org\/10.1038\/cddis.2013.488","journal-title":"Cell Death Dis"},{"key":"2409_CR283","doi-asserted-by":"publisher","first-page":"22541","DOI":"10.1038\/s41598-024-73394-9","volume":"14","author":"L Hong","year":"2024","unstructured":"Hong L, Tanaka M, Yasui M, Hara-Chikuma M (2024) HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression. Sci Rep 14:22541. https:\/\/doi.org\/10.1038\/s41598-024-73394-9","journal-title":"Sci Rep"},{"key":"2409_CR284","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","volume":"9","author":"T Knox","year":"2019","unstructured":"Knox T, Sahakian E, Banik D et al (2019) Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep 9:6136. https:\/\/doi.org\/10.1038\/s41598-019-42237-3","journal-title":"Sci Rep"},{"key":"2409_CR285","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/annonc\/mdv066","volume":"26","author":"S Fu","year":"2015","unstructured":"Fu S, Hou MM, Naing A et al (2015) Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol 26:1012\u20131018. https:\/\/doi.org\/10.1093\/annonc\/mdv066","journal-title":"Ann Oncol"},{"key":"2409_CR286","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1038\/s41598-020-58366-z","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Janku F, Piha-Paul S et al (2020) Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep 10:3080. https:\/\/doi.org\/10.1038\/s41598-020-58366-z","journal-title":"Sci Rep"},{"key":"2409_CR287","doi-asserted-by":"publisher","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","volume":"12","author":"T Hennika","year":"2017","unstructured":"Hennika T, Hu G, Olaciregui NG et al (2017) Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS ONE 12:e0169485. https:\/\/doi.org\/10.1371\/journal.pone.0169485","journal-title":"PLoS ONE"},{"key":"2409_CR288","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1186\/s12885-015-1967-5","volume":"15","author":"G Greve","year":"2015","unstructured":"Greve G, Schiffmann I, Pfeifer D et al (2015) The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer 15:947. https:\/\/doi.org\/10.1186\/s12885-015-1967-5","journal-title":"BMC Cancer"},{"key":"2409_CR289","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1158\/0008-5472.CAN-13-1079","volume":"75","author":"S Zhang","year":"2015","unstructured":"Zhang S, Zhou L, Hong B et al (2015) Small molecule NSC59984 restores p53 pathway signaling and anti-tumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res 75:3842\u20133852. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1079","journal-title":"Cancer Res"},{"key":"2409_CR290","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1158\/1541-7786.MCR-21-0149","volume":"20","author":"S Zhang","year":"2022","unstructured":"Zhang S, Zhou L, El-Deiry WS (2022) Small-molecule NSC59984 induces mutant p53 degradation through a ROS-ERK2-MDM2 axis in cancer cells. Mol Cancer Res 20:622\u2013636. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0149","journal-title":"Mol Cancer Res"},{"key":"2409_CR291","doi-asserted-by":"publisher","first-page":"e2078","DOI":"10.1002\/cnr2.2078","volume":"7","author":"S Tripathi","year":"2024","unstructured":"Tripathi S, Gupta E, Galande S (2024) Statins as anti-tumor agents: a paradigm for repurposed drugs. Cancer Rep 7:e2078. https:\/\/doi.org\/10.1002\/cnr2.2078","journal-title":"Cancer Rep (Hoboken)"},{"key":"2409_CR292","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/ph13120422","volume":"13","author":"A Markowska","year":"2020","unstructured":"Markowska A, Antoszczak M, Markowska J, Huczy\u0144ski A (2020) Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women. Pharmaceuticals 13:422. https:\/\/doi.org\/10.3390\/ph13120422","journal-title":"Pharmaceuticals (Basel)"},{"key":"2409_CR293","doi-asserted-by":"publisher","first-page":"1340634","DOI":"10.3389\/fimmu.2023.1340634","volume":"14","author":"W Du","year":"2024","unstructured":"Du W, Xia X, Hu F, Yu J (2024) Extracellular matrix remodeling in the tumor immunity. Front Immunol 14:1340634. https:\/\/doi.org\/10.3389\/fimmu.2023.1340634","journal-title":"Front Immunol"},{"key":"2409_CR294","doi-asserted-by":"publisher","first-page":"878377","DOI":"10.3389\/fonc.2022.878377","volume":"12","author":"R Hernandez","year":"2022","unstructured":"Hernandez R, Malek TR (2022) Fueling cancer vaccines to improve T cell-mediated antitumor immunity. Front Oncol 12:878377. https:\/\/doi.org\/10.3389\/fonc.2022.878377","journal-title":"Front Oncol"},{"key":"2409_CR295","doi-asserted-by":"publisher","first-page":"107720","DOI":"10.1016\/j.pharmthera.2020.107720","volume":"220","author":"J Huang","year":"2021","unstructured":"Huang J (2021) Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol Ther 220:107720. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107720","journal-title":"Pharmacol Ther"},{"key":"2409_CR296","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1158\/1078-0432.CCR-11-1817","volume":"17","author":"MN Fishman","year":"2011","unstructured":"Fishman MN, Thompson JA, Pennock GK et al (2011) Phase I trial of ALT-801, an interleukin-2\/T-cell receptor fusion protein targeting p53 (aa264-272)\/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 17:7765\u20137775. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1817","journal-title":"Clin Cancer Res"},{"key":"2409_CR297","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","volume":"14","author":"X Qin","year":"2024","unstructured":"Qin X, Ning W, Liu H et al (2024) Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharm Sin B 14:2361\u20132377. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.027","journal-title":"Acta Pharm Sin B"},{"key":"2409_CR298","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-021-00635-y","volume":"6","author":"C Yang","year":"2021","unstructured":"Yang C, Lou G, Jin W-L (2021) The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies. Signal Transduct Target Ther 6:219. https:\/\/doi.org\/10.1038\/s41392-021-00635-y","journal-title":"Signal Transduct Target Ther"},{"key":"2409_CR299","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","volume":"23","author":"A Kong","year":"2021","unstructured":"Kong A, Mehanna H (2021) WEE1 inhibitor: clinical development. Curr Oncol Rep 23:107. https:\/\/doi.org\/10.1007\/s11912-021-01098-8","journal-title":"Curr Oncol Rep"},{"key":"2409_CR300","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ymthe.2018.11.006","volume":"27","author":"H Echchannaoui","year":"2019","unstructured":"Echchannaoui H, Petschenka J, Ferreira EA et al (2019) A potent tumor-reactive p53-specific single-chain TCR without on- or off-target autoimmunity in vivo. Mol Ther 27:261\u2013271. https:\/\/doi.org\/10.1016\/j.ymthe.2018.11.006","journal-title":"Mol Ther"},{"key":"2409_CR301","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG (2018) Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer 18:89\u2013102. https:\/\/doi.org\/10.1038\/nrc.2017.109","journal-title":"Nat Rev Cancer"},{"key":"2409_CR302","doi-asserted-by":"publisher","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","volume":"113","author":"MR Bauer","year":"2016","unstructured":"Bauer MR, Joerger AC, Fersht AR (2016) 2-sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci USA 113:E5271\u20135280. https:\/\/doi.org\/10.1073\/pnas.1610421113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2409_CR303","doi-asserted-by":"publisher","unstructured":"Schram AM, Fellous M, LeDuke K et al (2025) PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation. Future Oncol 21:3159\u20133166. https:\/\/doi.org\/10.1080\/14796694.2025.2557176","DOI":"10.1080\/14796694.2025.2557176"},{"key":"2409_CR304","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1021\/acsmedchemlett.4c00379","volume":"16","author":"BT Vu","year":"2025","unstructured":"Vu BT, Dominique R, Fahr BJ et al (2025) Discovery of rezatapopt (PC14586), a first-in-class, small-molecule reactivator of p53 Y220C mutant in development. ACS Med Chem Lett 16:34\u201339. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00379","journal-title":"ACS Med Chem Lett"},{"key":"2409_CR305","doi-asserted-by":"publisher","first-page":"6847","DOI":"10.1021\/acs.jmedchem.5c00670","volume":"68","author":"Z Ma","year":"2025","unstructured":"Ma Z, Shen Q, Zhou J (2025) Rezatapopt (PC14586): a first-in-class small molecule p53 Y220C mutant protein stabilizer in clinical trials. J Med Chem 68:6847\u20136849. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00670","journal-title":"J Med Chem"},{"key":"2409_CR306","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biom15060763","volume":"15","author":"N Zhang","year":"2025","unstructured":"Zhang N, Jing Z, Song J et al (2025) Discovery of drugs targeting mutant p53 and progress in nano-enabled therapeutic strategy for p53-mutated cancers. Biomolecules 15:763. https:\/\/doi.org\/10.3390\/biom15060763","journal-title":"Biomolecules"},{"key":"2409_CR307","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm0302-282","volume":"8","author":"VJN Bykov","year":"2002","unstructured":"Bykov VJN, Issaeva N, Shilov A et al (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282\u2013288. https:\/\/doi.org\/10.1038\/nm0302-282","journal-title":"Nat Med"},{"key":"2409_CR308","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fonc.2016.00021","volume":"6","author":"VJN Bykov","year":"2016","unstructured":"Bykov VJN, Zhang Q, Zhang M et al (2016) Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol 6:21. https:\/\/doi.org\/10.3389\/fonc.2016.00021","journal-title":"Front Oncol"},{"key":"2409_CR309","doi-asserted-by":"publisher","first-page":"593383","DOI":"10.3389\/fonc.2020.593383","volume":"10","author":"P Monti","year":"2020","unstructured":"Monti P, Menichini P, Speciale A et al (2020) Heterogeneity of TP53 mutations and P53 protein residual function in cancer: does it matter? Front Oncol 10:593383. https:\/\/doi.org\/10.3389\/fonc.2020.593383","journal-title":"Front Oncol"},{"key":"2409_CR310","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R et al (2021) Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM). J Clin Oncol 39:1575\u20131583. https:\/\/doi.org\/10.1200\/JCO.20.02342","journal-title":"J Clin Oncol"},{"key":"2409_CR311","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.sbi.2020.11.005","volume":"67","author":"\u00d6 Demir","year":"2021","unstructured":"Demir \u00d6, Barros EP, Offutt TL et al (2021) An integrated view of p53 dynamics, function, and reactivation. Curr Opin Struct Biol 67:187\u2013194. https:\/\/doi.org\/10.1016\/j.sbi.2020.11.005","journal-title":"Curr Opin Struct Biol"},{"key":"2409_CR312","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41418-024-01391-6","volume":"32","author":"AC Joerger","year":"2025","unstructured":"Joerger AC, Stiewe T, Soussi T (2025) TP53: the unluckiest of genes? Cell Death Differ 32:219\u2013224. https:\/\/doi.org\/10.1038\/s41418-024-01391-6","journal-title":"Cell Death Differ"},{"key":"2409_CR313","doi-asserted-by":"publisher","first-page":"8879","DOI":"10.18632\/oncotarget.2432","volume":"5","author":"X Yu","year":"2014","unstructured":"Yu X, Blanden AR, Narayanan S et al (2014) Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget 5:8879\u20138892. https:\/\/doi.org\/10.18632\/oncotarget.2432","journal-title":"Oncotarget"},{"key":"2409_CR314","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1124\/mol.114.097550","volume":"87","author":"AR Blanden","year":"2015","unstructured":"Blanden AR, Yu X, Wolfe AJ et al (2015) Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol Pharmacol 87:825\u2013831. https:\/\/doi.org\/10.1124\/mol.114.097550","journal-title":"Mol Pharmacol"},{"key":"2409_CR315","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/cancers10060188","volume":"10","author":"R Schulz-Heddergott","year":"2018","unstructured":"Schulz-Heddergott R, Moll UM (2018) Gain-of-function (GOF) mutant p53 as actionable therapeutic target. Cancers 10:188. https:\/\/doi.org\/10.3390\/cancers10060188","journal-title":"Cancers (Basel)"},{"key":"2409_CR316","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W et al (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14:157. https:\/\/doi.org\/10.1186\/s13045-021-01169-0","journal-title":"J Hematol Oncol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02409-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02409-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02409-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:10:02Z","timestamp":1789672202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02409-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":316,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2409"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02409-9","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"212"}}